

AWARD NUMBER: W81XWH-19-1-0527

TITLE: Direct Regulation of Estrogen Receptor Transcription Activity by NF1

PRINCIPAL INVESTIGATOR: Eric Chang

CONTRACTING ORGANIZATION: Baylor College of Medicine, Houston, TX

REPORT DATE: October 2020

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188		
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE October 2020		2. REPORT TYPE Annual		3. DATES COVERED 01Sep2019-31Aug2020	
4. TITLE AND SUBTITLE Direct Regulation of Estrogen Receptor Transcription Activity by NF1			5a. CONTRACT NUMBER W81XWH-19-0527		
			5b. GRANT NUMBER		
			5c. PROGRAM ELEMENT NUMBER		
6. AUTHOR(S) Eric Chang E-Mail: echang1@bcm.edu ;			5d. PROJECT NUMBER 0011355180		
			5e. TASK NUMBER		
			5f. WORK UNIT NUMBER		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Baylor College of Medicine One Baylor Plaza, BCM600 Houston, TX 77030-3411			8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSOR/MONITOR'S ACRONYM(S)		
			11. SPONSOR/MONITOR'S REPORT NUMBER(S)		
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT This project centers on the NF1/neurofibromin tumor suppressor, which was best known as a GTPase Activating Protein (GAP) that repress Ras activity. The parent DoD award has successfully defined a new and GAP-independent activity that NF1 is also a transcriptional co-repressor for estrogen receptor α (ER) in ER ⁺ breast cancer. While the parent DoD award focused on endocrine therapy resistance caused by NF1 loss, in this Expansion Award, the focus instead is on metastasis, for which currently has no cure. An important feature of ER ⁺ breast cancer metastasis is that greater than 70% of the metastasis is in the bone. We hypothesized that the transcriptional co-repressor role of NF1 is also responsible for driving bone metastasis in ER ⁺ breast cancer. Therefore, the objective of this Expansion Award is to assess NF1's role in metastasis in order to establish a strategy to stop it. We have made progress in accomplish Task1/Aim 1 to fully define NF1-controlled genes that can impact bone metastasis. This was a key part of the data that was just published in the high impact journal <i>Cancer Cell</i> . This award has also supported the launching a Phase-II clinical trial to treat ER ⁺ NF1-depleted breast cancer, and the awards of a SPORE and another DoD Level-2 project. However, in Aim 2 (Tasks 2 and 30) we are dependent on the use of animals to study how NF1-depleted cancer cells interact with the bone, but this line of study has been severely and negatively impacted by COVID-19. We discuss how we plan to overcome this problem in the future.					
15. SUBJECT TERMS					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
Unclassified	Unclassified	Unclassified	Unclassified	32	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
1. Introduction	2
2. Keywords.....	2
3. Accomplishments	2
4. Impact.....	4
5. Changes/Problems	4
6. Products.....	4
7. Participants & Other Collaborating Organizations.....	6

INTRODUCTION

This project centers on the NF1/neurofibromin tumor suppressor, which was best known as a GTPase Activating Protein (GAP) that repress Ras activity. The parent DoD award has successfully defined a new and GAP-independent activity that NF1 is also a transcriptional co-repressor for estrogen receptor α (ER) in ER⁺ breast cancer. While the parent DoD award focused on endocrine therapy resistance caused by NF1 loss, in this Expansion Award, the focus instead is on metastasis, for which currently has no cure. An important feature of ER⁺ breast cancer metastasis is that greater than 70% of the metastasis is in the bone. We **hypothesized** that the transcriptional co-repressor role of NF1 is also responsible for driving bone metastasis in ER⁺ breast cancer. Therefore, the **objective** of this Expansion Award is to assess NF1's role in metastasis in order to establish a strategy to stop it. The specific aims are:

AIM 1: To define the full range of NF1 transcriptional activity in ER⁺ breast cancer cells by identifying key metastasis-driving genes that are directly regulated by NF1.

AIM 2: To assess the impact of NF1 depletion on bone metastasis using BICA (bone in culture assay) *in vitro* and IIA (intra iliac artery) injection *in vivo*, and how to block these activities in order to reduce metastasis in ER⁺ NF1⁻ cancer.

KEYWORDS

4-OHT, 4-hydroxytamoxifen
AI, Aromatase inhibitor
BICA, bone in culture assay
ChIP, Chromatin immunoprecipitation
DOX, doxycycline.
E2, estrogen/estradiol
EMT, epithelial to mesenchymal transition
ER, estrogen receptor- α
EREs, Estrogen Response Elements
FS, frameshift
GAP, GTPase Activating Protein
HR, hazard ratio HR
IHC, immunohistochemistry
IIA, Intra-iliac artery
KI, knock-in
KM, Kaplan-Meier
KO, knock-out
MS, missense
NF1, Neurofibromatosis type 1
NS, nonsense
PDX, patient-derived xenograft
SERD, Selective ER Degradator
SERM, Selective ER modulator
TCGA, The Cancer Genome Atlas

ACCOMPLISHMENTS

Major task 1: Identify gene expression directly control by NF1.

NF1 is an ER co-repressor for transcription regulation; thus, we sought gene expression changes after NF1-depletion. This line of research has mostly been published in a paper of ours in the high impact journal *Cancer Cell* (Zheng et al 2020, see “Products” below). The key findings regarding this is summarized as follows:

(1) NF1-depletion enhances ER-dependent gene expression in response to ligand. We first analyzed gene expression by qPCR in 3 ER⁺ breast cancer cell and found that when NF1 is depleted (by either shRNA or CRISPR K/O), expression of several well known E2-response genes increased in the presence of E2. We then analyzed global gene expression changes using RNA-seq in the MCF-7 model and found that expression of known E2-induced genes was more strongly induced while expression of known E2-repressed genes was more strongly repressed. These results strongly support the hypothesis that NF1 is an ER co-repressor such that its loss globally enhances ER-dependent gene expression.

Table 1. NF1-repressible genes are enriched with “bone remodeling” and bone “ossification” activities.			
Gene Set Name	Description	Rank in NF1-KD unique E2 regulon	Rank in Common E2 regulon
Computational gene set			
MODULE_137	CNS genes.	5	>50
MODULE_12	Spinal cord (neuro-development) genes.	13	>50
MODULE_2	DRG (dorsal root ganglia) genes.	16	27
MODULE_234	Bone remodeling.	35	49
GO gene set			
GO_NEUROGENESIS	Generation of cells within the nervous system	6	>50
GO_OSSIFICATION	The formation of bone or of a bony substance, or the conversion of fibrous tissue or of cartilage into bone or a bony substance	14	>50
GO_NEURON_DIFFERENTIATION	The process in which a relatively unspecialized cell acquires specialized features of a neuron.	15	>50
GO_NEURON_DEVELOPMENT	The process whose specific outcome is the progression of a neuron over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell.	23	>50
GO_NEURON_PROLONGATION	A prolongation or process extending from a nerve cell, e.g. an axon or dendrite.	46	>50

(2) NF1-repressible genes found in the MCF-7 cell line model agree with those found in NF1-deficient breast tumors in patient databases. We obtained a list of “NF1-repressible” genes from ER⁺ breast tumors in METABIC and TCGA by examining genes in tumors that contain a wild type *NF1* gene or a mutant *NF1* gene with a NS/FS mutation. This patient-derived lists of “NF1-repressed” genes overlap substantially with those found in the MCF-7 model as described above. Thus, NF1 loss in patients similarly de-represses gene expression controlled by ER.

(3) NF1-repressed genes are enriched with those that can influence EMT and bone-physiology. As reported in the paper, we already detected an EMT signature to be enriched in NF1-repressed gene sets, both found in the cell lines and in patients. EMT is a key feature often associates with metastasis, the main focus of this project.




Fig. 1. *PTH1R* expression was highly induced after NF1-depletion in MCF-7 cell. MCF-7 cells carrying a DOX-inducible shRNA against *NF1* were seeded in E2-deprived medium to which either vehicle or E2 was added. mRNA samples were made, and *PTH1R* levels were measured by qPCR.

We have new preliminary data by performing GESA and found enrichment of “bone remodeling” and bone “ossification” as a top gene function set (Table. 1), supporting the hypothesis that NF1 regulates bone physiology as a means to influence bone metastasis. To validate the RNA-seq data by qPCR in order to identify drivers for promoting bone metastasis, we assessed expression levels of the *PTH1R* gene, which encodes parathyroid hormone 1 receptor, a G-protein coupled receptor with 7 transmembrane helices. *PTH1R* and its cognate receptor *PTHrP* are critical for bone remodeling. As shown in Fig. 1, while *PTH1R* induction was not readily detectable in NF1⁺ cells after E2 stimulation, *PTH1R* expression increased nearly 9 folds in NF1-depleted cells. Supporting the concept that NF1 loss in ER⁺ breast cancer patients also induces *PTH1R* expression, we found in the CPTAC breast prospective samples that high *PTH1R* levels correlated with low *NF1* levels primarily in luminal ER⁺ breast tumors (Fig. 2). Finally, we examined *PTH1R* mRNA levels in a data base containing paired primary vs. metastatic tumors in different organs (https://github.com/leeoesterreich/npjBreast_2019), and found that high *PTH1R* levels are enriched in metastasis to the bone but not to other organs (Fig. 3).

Major task 2: Assess NF1’s role in bone metastasis *in vitro* using BICA.

A BICA assay was developed to measure how well cancer cells grow in bone in an *in vitro* environment. Briefly, cancer cells tagged by a luciferase reporter are injected via the intra-iliac artery (IIA) to be delivered to the hind leg bone in mice. The injected bones are harvested the next day, fragmented, and randomized to be seeded in 96 -well plates. Cell growth is then measured by luciferase activity. In preliminary study submitted




Fig. 2. Inverse correlation between *NF1* and *PTH1R* levels in CPTAC prospective breast cancer database. Note the negative Pearson correlation is only statistically significant when luminal tumors were considered.




Fig. 3. *PTH1R* levels are particularly high in bone metastases. *PTH1R* mRNAs in paired primary vs metastasis in different organs were analyzed. *PTH1R* levels are particularly high in bone metastasis.

manner has been published in a high impact journal *Cancer Cell*:

Zheng ZY, Anurag M, Lei JT, Cao J, Singh P, Peng J, Kennedy H, Nguyen NC, Chen Y, Lavere P, Li J, Du XH, Cakar B, Song W, Kim BJ, Shi J, Seker S, Chan DW, Zhao GQ, Chen X, Banks KC, Lanman RB, Shafae MN, Zhang XH, Vasaikar S, Zhang B, Hilsenbeck SG, Li W, Foulds CE, Ellis MJ, Chang EC: Neurofibromin Is an estrogen receptor-alpha transcriptional co-repressor in breast cancer. *Cancer Cell* 37:387-402, 2020. This paper is attached at the end of the report.

Clinical Trial: Based on our compelling pre-clinical data, we designed a two-cohort phase II study of fulvestrant-binimetinib combination in patients with metastatic ER⁺ breast cancers in collaboration with the NCI Combo MATCH program (Protocol #EAY191-N2). This trial design is approved by NCI Cancer Therapy Evaluation Program (CTEP) as one of ComboMATCH therapeutic arms with a projected initiation date in Q1 2021. ComboMATCH is a highly competitive program designed to study combinatorial therapeutics in advanced cancers rationally designed based on robust predictive biomarkers-guided selection of target population.

Grants awarded due to the support by this project:

1. An NF1-themed project is Project-1 in an NCI breast cancer SPORE that was just awarded to us:

Project Title: Translational Research in Breast Cancer (2P50CA186784-06A1). The objectives of this project are thus to identify treatment-resistance drivers in ER⁺ breast cancer and to target their therapeutic vulnerabilities. The total award is >\$11 million in total cost.

2. While working on ER regulation by NF1, we observe that NF1 can also repress the structurally related androgen receptor (AR). We are just rewarded another Level-2 DoD award to study this interaction.


Project Title: Therapeutic Targeting of Nuclear Hormone Receptors in Neurofibromin/NF1-Depleted Breast Cancer (BC200589). The overall objective of this project is to assess what therapeutic opportunities are associated with neurofibromin loss in patients. The total award is

PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS:

Name	Project role	ORCID ID	Person Mon worked	Project contribution	Funding support
Eric Chang	PI	0000-0002-1375-5088	3.0	Design and execute all the studies in this project, and will write the paper.	This grant.
Zeyi Zheng	Staff Scientist	0000-0001-6536-4874	4.82	Assist Dr. Chang in the design and execution of all the studies in this project, and supervise Ms. Kenney	This grant.
Hilda Kennedy	Tech	NA	4.82	Provide technical support on all projects.	This grant
Zhao, Zifan	Graduate Student	0000-0002-1901-2752	2.0	A new graduate student who is responsible for Aim 1.	This grant
Hai Wang	Instructor	0000-0003-2063-2008	0.9	Assist Dr. Chang in the BICA and IIA injection studies.	This grant.

Neurofibromin Is an Estrogen Receptor- α Transcriptional Co-repressor in Breast Cancer

Graphical Abstract



Authors

Ze-Yi Zheng, Meenakshi Anurag, Jonathan T. Lei, ..., Charles E. Foulds, Matthew J. Ellis, Eric C. Chang

Correspondence

echang1@bcm.edu (E.C.C.),
mjellis@bcm.edu (M.J.E.)

In Brief

Zheng et al. find that the Ras-GAP NF1 is also a transcriptional co-repressor of estrogen receptor α (ER). NF1 loss leads to estradiol hypersensitivity and tamoxifen agonism. A selective ER degrader and MEK inhibitor combination induces tumor regression in mouse models of NF1-deficient ER⁺ breast cancer.

Highlights

- NF1 is a GAP-independent estrogen receptor transcription co-repressor
- Somatic NF1 loss causes tamoxifen/aromatase inhibitor resistance in ER⁺ breast cancer
- A MEK inhibitor plus a SERD is effective in NF1⁻ ER⁺ PDX and cell line models



Neurofibromin Is an Estrogen Receptor- α Transcriptional Co-repressor in Breast Cancer

Ze-Yi Zheng,¹ Meenakshi Anurag,¹ Jonathan T. Lei,^{1,2} Jin Cao,³ Purba Singh,¹ Jianheng Peng,^{1,4} Hilda Kennedy,¹ Nhu-Chau Nguyen,¹ Yue Chen,⁵ Philip Lavere,³ Jing Li,¹ Xin-Hui Du,^{1,6} Burcu Cakar,¹ Wei Song,¹ Beom-Jun Kim,¹ Jiejun Shi,¹ Sinem Seker,¹ Doug W. Chan,^{1,3} Guo-Qiang Zhao,⁶ Xi Chen,³ Kimberly C. Banks,⁷ Richard B. Lanman,⁷ Maryam Nemati Shafaei,¹ Xiang H.-F. Zhang,^{1,3} Suhas Vasaikar,¹ Bing Zhang,¹ Susan G. Hilsenbeck,¹ Wei Li,¹ Charles E. Foulds,^{3,8} Matthew J. Ellis,^{1,3,9,10,*} and Eric C. Chang^{1,3,10,11,*}

¹Lester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA

²Interdepartmental Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, TX, USA

³Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA

⁴Department of Physical Examination, the First Affiliated Hospital of Chongqing Medical University, Chongqing, P.R. China

⁵Adrienne Helis Malvin Medical Research Foundation, New Orleans, LA, USA

⁶Department of Bone and Soft Tissue, Zhengzhou University Affiliated Henan Cancer Hospital and College of Basic Medical Sciences, Zhengzhou University, Zhengzhou, P. R. China

⁷Guardant Health, Redwood City, CA, USA

⁸Center for Precision Environmental Health, Baylor College of Medicine, Houston, TX, USA

⁹Department of Medicine, Baylor College of Medicine, Houston, TX, USA

¹⁰These authors contributed equally

¹¹Lead Contact

*Correspondence: echang1@bcm.edu (E.C.C.), mjellis@bcm.edu (M.J.E.)

<https://doi.org/10.1016/j.ccell.2020.02.003>

SUMMARY

We report that neurofibromin, a tumor suppressor and Ras-GAP (GTPase-activating protein), is also an estrogen receptor- α (ER) transcriptional co-repressor through leucine/isoleucine-rich motifs that are functionally independent of GAP activity. GAP activity, in turn, does not affect ER binding. Consequently, neurofibromin depletion causes estradiol hypersensitivity and tamoxifen agonism, explaining the poor prognosis associated with neurofibromin loss in endocrine therapy-treated ER⁺ breast cancer. Neurofibromin-deficient ER⁺ breast cancer cells initially retain sensitivity to selective ER degraders (SERDs). However, Ras activation does play a role in acquired SERD resistance, which can be reversed upon MEK inhibitor addition, and SERD/MEK inhibitor combinations induce tumor regression. Thus, neurofibromin is a dual repressor for both Ras and ER signaling, and co-targeting may treat neurofibromin-deficient ER⁺ breast tumors.

INTRODUCTION

Germline mutations in the *NF1* (neurofibromatosis type 1) gene are responsible for neurofibromatosis type 1, the most common inherited disorder that predisposes individuals to both benign

and malignant tumors of the nervous system (Ratner and Miller, 2015), as well as an increased risk for breast cancer (Madanik et al., 2012; Salemis et al., 2010; Sharif et al., 2007). Analysis of The Cancer Genome Atlas (TCGA) data has shown that *NF1* is mutated in a wide range of common cancers (e.g., melanoma,

Significance

Neurofibromin is a co-repressor of estrogen receptor (ER), therefore loss enhances ER transcriptional activity. Loss-of-function mutations in the *NF1* gene promote tamoxifen agonism and estrogen deprivation resistance. Although ER⁺ NF1-depleted cells are initially responsive to fulvestrant, a selective ER degrader, enhanced Ras activity promotes acquired resistance. When Ras pathway activation is inhibited with a well-tolerated MEK inhibitor, fulvestrant resistance is reversed and full tumor regression ensues. Thus, neurofibromin depletion represents a distinct breast cancer subset where the choice of endocrine treatment may be critical, and MEK inhibitor combinations require clinical investigation. A role as a dual repressor for both Ras and ER may also explain the sexually dimorphic characteristics of neurofibromatosis where tumorigenesis is promoted by female puberty.



lymphoma, and cancers of the lung, breast, and colon) (Yap et al., 2014). Thus, *NF1* deficiency underlies the formation and/or progression of a large number of cancers.

NF1 encodes neurofibromin, an established GTPase-activating protein (GAP), that attenuates Ras signaling (Maertens and Cichowski, 2014). The human genome contains up to 14 Ras GAPs that share no significant sequence homology beyond the GAP domain. However, across species there is extensive evolutionary sequence conservation outside of the relatively small GAP domain (e.g., 83% overall identity in amino acid sequence between human and salmon neurofibromins), suggesting that neurofibromin has other yet undisclosed functional domains.

Approximately 80% of breast cancers are positive for estrogen receptor- α (ER⁺), a ligand-dependent transcription factor that is activated by estradiol (E2) (Feng and O'Malley, 2014). The E2-liganded ER recruits co-activators (such as steroid receptor co-activators, SRC-1-3) to estrogen-responsive elements (EREs) in ER-regulated genes. Tamoxifen, a selective ER modulator (SERM), is predominantly antagonistic in breast cancer cells, hence its therapeutic effect. When tamoxifen binds to ER, co-activators are displaced by co-repressors in the ER-ERE complex (Shang et al., 2000). Established ER co-repressors bind ER via their leucine/isoleucine-rich motifs, and substitutions of L or I with an A can disrupt binding (Hu and Lazar, 1999). Interactions are also mediated by electrostatic interactions (Heldring et al., 2007; Shiau et al., 1998).

Besides tamoxifen, ER⁺ breast cancer can be treated with estrogen deprivation through ovarian suppression and aromatase inhibition (AI), and ER can be directly targeted by selective ER degraders (SERDs), such as fulvestrant, which induce ER protein turnover. However, relapse is common, and the majority of breast cancer deaths occur after a diagnosis of an ER⁺ primary cancer.

RESULTS

***NF1* Loss Correlates with Poor Patient Outcome in ER⁺ Breast Cancer**

While *NF1* mutation frequencies are low in primary ER⁺ breast cancer (2% in TCGA [TCGA, 2012] as shown in Figure 1A, and 4% in our patient cohort [Griffith et al., 2018]), *NF1* mutation frequency is higher in metastatic ER⁺ breast cancer patients ($n = 535$) (Lanman et al., 2015; Zill et al., 2018) when circulating cell-free tumor DNA (ctDNA) was sequenced (18%; Figure 1A; Table S1). Similar enrichment of *NF1* mutations in metastatic ER⁺ breast cancer has been reported by others (Bertucci et al., 2019; Meric-Bernstam et al., 2014; Pearson et al., 2019; Razavi et al., 2018; Sokol et al., 2019; Yates et al., 2017). These observations suggest that somatic *NF1* events are an important class of mutations driving breast cancer progression.

We have previously analyzed somatic mutations in primary tumors accrued from ER⁺ breast cancer patients treated with adjuvant tamoxifen monotherapy and found that *NF1* nonsense and frameshift mutations were associated with a markedly higher risk of breast cancer recurrence and death (Griffith et al., 2018). No GAP-inactivating missense mutations were found. When examining the COSMIC database, a C to T nonsense mutation at R2450 (*R2450**) is the most frequent non-silent *NF1* mutation,

found 28 times (Figure S1A). Nonsense/frameshift mutations can trigger mRNA degradation through nonsense-mediated decay. Consistent with this mechanism, greatly reduced full-length *NF1* mRNA levels were observed in both TCGA (Figure 1B) and METABRIC (Curtis et al., 2012) (Figure S1B) samples when nonsense/frameshift mutations were present. Similar reduction of *NF1* mRNA in tumors carrying *NF1* mutations have also been reported in another patient cohort (Pearson et al., 2019). ER⁺ breast cancer is also treated with AI; therefore, we examined gene expression data from the ACOSOG Z1031 clinical trial, where patients were treated with an AI before surgery (Ellis et al., 2011). These data demonstrated that while a multigene proliferation score (MGPS) (Ellis et al., 2017) decreased after AI treatment in tumors with higher *NF1* mRNA levels, reduced suppression of proliferation (high MGPS) was observed in tumors with low *NF1* mRNA levels, indicating AI resistance (Figure 1C; Table S2). Finally, we found that *NF1* proteins missing a small portion of the C terminus caused by the *NF1-R2450** mutation or by two other recurrent nonsense/frameshift mutations, *NF1-R2258** and *NF1-Y2285** (Figure S1A), could not be efficiently expressed unless a proteasome inhibitor was added (Figure S1C), supporting the possibility that some C-terminally truncated *NF1* proteins may be unstable.

Collectively, these findings raise the possibility that depletion of neurofibromin is a common consequence of nonsense/frameshift mutations and most associated with poor outcomes. Importantly, sequencing studies have found few recurrent inactivating mutations in the *NF1* GAP domain, leading us to speculate that *NF1* protein may harbor additional negative regulatory functions relevant to breast cancer pathogenesis.

***NF1* Depletion Promotes Tamoxifen Agonism and E2 Hypersensitivity in ER⁺ Breast Cancer Cells**

To investigate the consequences of *NF1* depletion on ER⁺ breast cancer, MCF-7 ER⁺ breast cancer cells were engineered to harbor lentiviruses expressing one of two doxycycline (DOX)-inducible small hairpin RNA (shRNA) clones (C5 and C6). Upon DOX addition (+DOX), *NF1* protein levels were reduced by ~70% as detected by a monoclonal antibody (mAb) we raised (Figures S1D and S1E). Increased ERK activating phosphorylation (pERK1/2) in DOX-treated cells versus vehicle-treated or scrambled shRNA controls indicated the anticipated reduction in GAP activity (Figure S1E). An *NF1* shRNA-resistant expression construct reversed these effects (Figure S1E).

Remarkably, when *NF1* expression was suppressed (+DOX) in MCF-7 cells as well as in two more ER⁺ breast cancer cell line, ZR-75B and T47D (Figure S1F), *in vitro* growth was consistently stimulated by 4-hydroxy-tamoxifen (4-OHT) under E2-deprived conditions (charcoal-stripped serum) (Figures 1D and S1G), in comparison with the non-silenced control (-DOX) or the scrambled shRNA +DOX control, indicating an *NF1* loss-mediated transition from 4-OHT antagonism to agonism. Furthermore, *NF1*-silenced cells proliferated at lower concentrations of E2 than controls, and higher E2 concentrations paradoxically inhibited cell growth indicating E2 hypersensitivity (Figures 1E and S1H). Two pools of *NF1* “knockout” (KO) MCF-7 cells were independently created by CRISPR-Cas9 (Figure S1D) with results similar to the shRNA data (Figures 1D and 1E). MDA-MB-231 cells are ER⁻, and *NF1* expression is barely




Figure 1. *NF1* Loss Promotes Tamoxifen Agonism and E2 Hypersensitivity Leading to Poor Patient Outcome in ER⁺ Breast Cancer

(A) The percentages of ER⁺ primary versus metastatic breast cancers carrying *NF1* mutations were analyzed by Fisher's exact test. NS and FS stand for nonsense and frameshift, respectively. The number of patients carrying a particular type of *NF1* mutation is shown at the upper left side of each column.

(B) Boxplot analysis of *NF1* mRNA levels in ER⁺ breast tumors carrying different *NF1* mutations in the RNA-seq database of TCGA. p value by Wilcoxon rank-sum test. The line in the middle of the box is the median. The box edges are the 25th and 75th percentiles and the whiskers denote 1.5 times the interquartile range.

(C) Patient samples were stratified by *NF1* mRNA levels according to TCGA definitions of high versus low expression (mean, 1.5 × SD). The boxplot analysis was similarly performed as in (B) to compare multigene proliferation score (MGPS) in tumors before treatment (BT) and on treatment (OT) with AI. The differences in MGPS before and during treatment in each *NF1* group were analyzed by the Wilcoxon signed-rank test. The differences in MGPS as a result of treatment between the two *NF1* groups were further analyzed by Wilcoxon rank-sum test.

(D) DOX-inducible gene silencing using *NF1* shRNA clone C5 and CRISPR-mediated *NF1*-KO were performed in MCF-7 cells. These cells were seeded in E2-deprived medium, to which 4-OHT was added, and cultured for 6 days. Cell numbers relative to vehicle control are plotted. Experiments were conducted as biological triplicates (n = 3 experiments), except for MCF-7 cells carrying *NF1* shRNA C5 (n = 8 experiments).

(E) Cell growth in response to E2 was similarly analyzed as in (D). n = 3 experiments, except for MCF-7 cells carrying *NF1* shRNA C5 (n = 8 experiments).

(F) MCF-7 cells carrying DOX-inducible *NF1* shRNA were transplanted into the mammary fat pads of ovariectomized nude mice, supplemented by an E2 capsule. When tumors appeared, the original E2 capsule was removed, and the resulting mice were randomized, DOX or vehicle treated. Each set was then treated by either tamoxifen (5 mg/mouse, left), or E2 (at two doses, middle). For *NF1*⁺ (–DOX) tumors, n = 10, 12, 12, and 8 mice per group for treatment of vehicle, 0.05 mg E2, 0.5 mg E2, and tamoxifen; for *NF1*^{KO} (+DOX) tumors, n = 10, 13, 11, and 8 mice per group. The inset shows *NF1*-silencing validation by qPCR 2 weeks post-DOX addition. On the far right, “Δ tumor volumes” between vehicle and either tamoxifen or E2 treated were analyzed by boxplot as in (C).

Data are reported as mean ± SEM. *p < 0.05, **p < 0.01 by pairwise two-tailed Student's t test, unless otherwise indicated. See also Figure S1 and Tables S1 and S2.

detectable (Ogata et al., 2001) due to a frameshift mutation (*NF1*-T467^{fs}) (Neve et al., 2006). These ER⁺ “*NF1*^{low}” cells were unresponsive to 4-OHT or E2, indicating a requirement for ER for the endocrine effects of *NF1* perturbation (Figures S1G and S1H). E2 hypersensitivity and 4-OHT agonism were reproduced *in vivo* using an MCF-7-based xenograft mouse model—tamoxifen stimulated the growth of *NF1*-silenced tumors (Figure 1F, left), and these tumors grew better than control tumors at a lower dose of E2 (0.05 mg dose) (Figure 1F, right).

NF1 Depletion Globally Enhances ER Transcriptional Activity

Because the abnormal E2 and tamoxifen responses observed in *NF1*-depleted cells are ER dependent, we investigated whether *NF1* depletion affects ER-dependent transcription. First, the mRNA levels of established ER target genes were examined by qPCR in MCF-7 cells, and the expression levels of *GREB1* and *pS2/TFF1* in the presence of E2 were elevated when *NF1* was depleted by DOX-inducible shRNA (Figure S2A) or CRISPR-mediated KO (Figure S2B). This increase was not due to an increase in ER protein levels and could be reversed by the shRNA-refractory *NF1* construct (“*NF1*-rescue,” Figure S2A), indicating the specificity of the shRNA targeting. Gene expression was also stimulated by 4-OHT in MCF-7 cells depleted for *NF1* by shRNA (Figure S2C) or by CRISPR (Figure S2B), consistent with conversion to agonism. E2- and 4-OHT-stimulated gene expression were similarly observed in *NF1*-silenced ZR-75B cells (Figure S2C). ER-dependent transcription is promoted by co-activators SRC1-3, and these factors can be selectively degraded by bufalin (Wang et al., 2014). Our data showed that bufalin inhibited 4-OHT-induced enhanced gene expression in *NF1*^{KD} MCF-7 cells (Figure S2D), indicating that SRC1-3 are required for this activity. Finally, we examined tumor tissues from the MCF-7 xenograft model (Figure 1E) by qPCR and found that expression of two ER target genes *GREB1* and *TFF1* was greatly enhanced when *NF1* was silenced (Figure S2E).

To examine the effects of *NF1* on gene expression in a genome-wide fashion, RNA sequencing (RNA-seq) experiments were performed in control (–DOX) and *NF1* knockdown (+DOX, KD) MCF-7 cells with and without E2 stimulation. Overall, E2 altered expression from 540 genes in the control *NF1*⁺ cells and 955 genes in *NF1*^{KD} cells (Figure 2A; Table S3). There was an overlap of 388 genes between the two gene sets (Table S3), indicating that expression changes of 72% (388/540) of the observed E2-altered genes seen in *NF1*⁺ cells were also altered in *NF1*^{KD} cells. These overlapping genes, referred to as the “common E2-regulon,” were analyzed by gene set enrichment analysis (GSEA) Hallmark Pathway analysis and found to be highly enriched with well-established E2-responsive genes (Figure 2A; Table S3). Furthermore, nearly all genes upregulated after E2 stimulation in *NF1*⁺ cells were more strongly induced in *NF1*^{KD} cells, and the great majority of E2-repressed genes were also more strongly repressed, consistent with bidirectional ER hyperactivity upon *NF1* depletion (Zubairy and Oesterreich, 2005). The 415 (955–540) E2-altered genes that were selectively observed in the *NF1*-depleted state (referred to as the “*NF1*^{KD}-unique E2-regulon”) were also assessed by GSEA Hallmark Pathway analysis (Table S3). Aside from a predominance of additional E2-regulated genes, a K-Ras-dependent gene

expression signature was also observed (Figure 2A). Gene expression changes induced by 4-OHT were also examined by RNA-seq. Although 4-OHT overall displays weak agonist activity as expected (Figure S2F; Table S3), the overlap of 4-OHT-altered gene expression between *NF1*⁺ and *NF1*^{KD} cells was 65% and enriched with well-established E2-responsive genes (Figure S2G). Furthermore, genes that were induced by 4-OHT in *NF1*⁺ cells were more highly induced, while 4-OHT-repressed genes were more strongly repressed in *NF1*^{KD} cells (Figure S2G).

To determine whether the E2-induced gene expression patterns shown in Figure 2A could be replicated in patient samples, differentially expressed genes according to *NF1* status (with or without *NF1* nonsense/frameshift mutation) in the METABRIC and TCGA ER⁺ datasets were identified, and pathway enrichments were similarly assessed (Table S4). The results were compared with the two MCF-7 E2-regulons described above. Supporting the conclusion that *NF1* depletion dramatically affects the expression of E2-responsive genes in clinical ER⁺ specimens, E2-responsive pathway terms were most significantly modulated by *NF1* mutation status, followed by the K-Ras signature (Figure 2B). A similar conclusion has been obtained by others after examining ER⁺ breast tumors with *NF1* shallow deletion in METABRIC (Dischinger et al., 2018) and *NF1* “truncating” mutations in TCGA (Pearson et al., 2019).


NF1 Depletion Increases ER Recruitment to EREs

In the presence of E2, *NF1* depletion mostly affects expression of known E2-responsive genes. To assess whether this is due to direct ER binding to the EREs, we performed chromatin immunoprecipitation (ChIP)-qPCR to analyze ER recruitment to ten well-documented ERE sites in six genes, *TFF1*, *GREB1*, *PGR*, *MYC*, *XBP1*, and *CCDN1*. The data show that *NF1* depletion enhances ER recruitment to all of these sites (Figures 2C and 2D).

In the presence of 4-OHT, expression of 542 genes was mostly detected in *NF1*^{KD} cells (Figure S2G). We examined one 4-OHT-dependent ER ChIP sequencing (ChIP-seq) dataset (He et al., 2018) and found that 68% of these 542 genes (371/542) were also found in this ER ChIP-seq study (Table S3). All together, these data suggest that *NF1* depletion mostly *quantitatively* enhances ER-dependent transcription, whether it is stimulated by E2 or 4-OHT, but *NF1* loss does not substantially qualitatively alter the profile of genes that get transcribed under the experimental conditions tested.

Neurofibromin Contains Two Leucine/Isoleucine-Rich Co-repressor Motifs

Tamoxifen agonism and E2 hypersensitivity, together with the RNA-seq and ER ChIP-seq data, suggested that neurofibromin may function as a ligand-dependent co-repressor for ER transcriptional activity. Consistent with this postulate, there are two consensus co-repressor motifs in neurofibromin, designated here as M1 and M2 (Figure 3A). Notably the ER binding motifs in neurofibromin family members appear to have co-evolved with emergence of estrogen-dependent reproduction. M1/2 are highly conserved in salmon, the most human-distant species examined to have an ER homolog (Rogers et al., 2000), but not in fly or yeast (Figure 3A), which do not. Furthermore, mutations affecting key residues in M1 and M2 can be found in cancer (COSMIC and METABRIC) and some of these



(legend on next page)

versa (Figure S3C). NF1⁺ MCF-7 cells were used to illustrate the point that these interactions were enhanced by 4-OHT, but reduced by E2; in contrast, ER could not be pulled down in the NF1-KO line, indicating that our neurofibromin mAb is specific (Figure 3B). Finally, M2 is located in the GAP domain, which can be readily purified from *Escherichia coli* (Bollag et al., 1993). We thus determined that 4-OHT increased the efficiency of the interaction between purified NF1-M2/GAP domain and purified ER in a pull-down, confirming that the interaction between NF1 and ER is very likely direct (Figure 3C).

The human genome contains 14 potential Ras GAPs, but they do not share sequence homology beyond the GAP domain. For example, in p120GAP/RASA1 there is no identifiable M1; nor was there an M2 in a published GAP domain alignment study (Ballester et al., 1990) (Figure S3D). Although ER co-immunoprecipitated NF1, ER did not co-immunoprecipitate p120/RASA1 (Figure S3C). Protein co-expression is a strong predictor for co-functionality (Wang et al., 2017a). Therefore, we assessed gene ontology molecular function terms of proteins whose levels positively correlated with those of neurofibromin from proteomics analysis of >100 breast cancer patient-derived samples (Clinical Proteomic Tumor Analysis Consortium) (Mertins et al., 2016). Whereas NF1 protein levels highly correlated with a number of transcription factor functionalities, and the “ligand-dependent nuclear receptor binding” term in particular, p120GAP, mostly negatively correlated with these factors (Figure S3E).

ER Binding and GAP Activity Are Two Independent Functions of Neurofibromin

To determine whether neurofibromin can directly interact with ER via M1/2 without a requirement for GAP activity or Ras pathway activation, we first took a pharmacological approach using Raf and MEK inhibitors, dabrafenib and trametinib (Robert et al., 2015). Here we found that Raf/MEK inhibition did not affect E2-dependent transcription measured by qPCR in either NF1⁺ or NF1-silenced MCF-7 cells (Figure S3F). Immunoblotting detected substantial loss of pERK levels by dabrafenib and trametinib, suggesting that the Ras-Raf pathway was efficiently inhibited in these experiments (Figure S3F). Bufalin, which promotes degradation of SRC1-3 co-activators, was the positive

control for this study. One of the best-known examples of a Ras-ER interaction is phosphorylation at serine 118 (pS118) in ER by ERK after growth factor stimulation (Kato et al., 1995). However, this event seems to be context (e.g., cell type and/or culture conditions)-dependent and can be catalyzed by other kinases (Anbalagan and Rowan, 2015). We could not detect a significant increase in ER-pS118 in NF1 KO MCF-7 cells, despite strong increase in activating phosphorylation in ERK1/2 (Figure S3G). Finally, we note that the average half maximal inhibitory concentration (IC₅₀) of trametinib in commonly used ER⁺ breast cancer cell lines under normal culture condition is 300 versus 0.05 μM in melanoma cells (<https://www.cancerrxgene.org>). Thus, under standard culture conditions, Ras-Raf signaling is not critical for either ER-dependent gene expression or growth of E2-sensitive ER⁺ breast cancer cells.

To directly ascertain whether M1 and M2 are authentic ER binding sites, residues I and V were substituted with A to create NF1-I417A-I418A and NF1-V1308A-V1309A. The I417M NF1 somatic M1 mutant found in an ER⁺ breast cancer was also generated. Conversely, two mutations found in metastatic breast cancer, NF1-R1362Q (Lanman et al., 2015) and NF1-K1444R (Li et al., 2013), were predicted (Wilkins et al., 2012) to inactivate GAP activity (Figure S3H). They were thus tested further to assess whether ER repression requires intact GAP activity. We confirmed that R1362Q and K1444R mutations greatly reduce the GAP activity of NF1, while the M1/2 mutations do not, by measuring pERK levels (Figure S3H).

Binding to ER (two-hybrid assay, Figure S3I) and repression of ER transcriptional activity (ERE-luciferase reporter assay [Hall and McDonnell, 1999]) (Figure S3J) were both greatly reduced by M1 and M2 mutations; in contrast, the two GAP mutants bound and suppressed ER activity as efficiently as wild-type NF1. One GAP and one M1 mutant were chosen for further study by expressing them in NF1-depleted cells to levels comparable with endogenous neurofibromin in control cells (Figure S3K). The enhanced *GREB1* and *TFF1* expression in NF1-silenced cells was completely repressed by wild-type NF1 and the GAP mutant, but only partially by the M1 mutant.

To ascertain whether ER repression and GAP activity are two independent functions of NF1 without using ectopic

Figure 3. Neurofibromin Binding to ER Is Selectively Mediated by Co-repressor Motifs

(A) Protein alignment was created by ClustalW (MUSCLE). NF1 has two potential co-repressor motifs, M1 and M2 (potential consensus sequences shown at the bottom). Mutations found in cancers (COSMIC) or neurofibromatosis are colored blue, and the numbers in parentheses are the number of times found in the COSMIC database.

(B) Parental MCF-7 or the NF1-KO (clone no. 1) MCF-7 cells were grown in E2-deprived medium to which E2, 4-OHT, or vehicle was added. Whole-cell or nuclear extracts were immunoprecipitated with NF1 or ER antibody, and the resulting samples were analyzed by immunoblotting. The number below the blot shows the percentage of co-immunoprecipitated protein.

(C) Recombinant purified ER-α preincubated with E2, 4-OHT, or vehicle was pulled down by amylose beads containing His-MBP-tagged NF1-M2/GAP domain, or His-MBP-GST control, and the results were analyzed by immunoblotting.

(D) Left: whole-cell lysates from parental MCF-7 cells (WT) or from a CRISPR “knockin” mutant carrying either an I417M (colored red) or an R1362Q (colored blue) mutation grown in full-serum medium were examined by immunoblotting to measure the pERK/total ERK ratios (below). Right: reciprocal co-immunoprecipitation experiments in the presence of 4-OHT similar to those in (B) assessed ER binding to various NF1 proteins.

(E) Parental or NF1 mutant cells were seeded in E2-deprived medium and were examined for cell growth in response to E2 or 4-OHT (6 days later) n = 3 experiments.

(F) *GREB1* and *TFF1* mRNA levels from parental or NF1 mutant cells treated with vehicle or E2 were measured by qPCR (n = 3 independent experiments). Expression levels were normalized to those of vehicle-treated wild-type cells. Data are reported as mean ± SEM. *p < 0.05, **p < 0.01 by pairwise two-tailed Student's t test. NS, not significant.

(G) mRNAs from cells seeded in charcoal-stripped serum were analyzed by RNA-seq. “E2-responsive genes” as defined in Figure 2A are shown on the left to which expression levels of genes (row Z scores from “log₂ transcripts per million” values) in various strains were aligned.

See also Figure S3 and Table S5.




Figure 4. ER Ligand-Mediated Nuclear Accumulation of Neurofibromin

(A) Left: whole-cell lysates from indicated cell lines treated with LMB were separated into nuclear (Nu.) and cytoplasmic (Cyt.) fractions. NF1, histone-3 (His. 3, nuclear marker), and GAPDH (cytoplasmic marker) were examined by immunoblotting. Right: NF1 levels in the cytoplasmic fraction (light blue) and the nuclear fraction (red) were normalized to GAPDH and His.-3, respectively, and the sum of these two fractions is defined as total NF1 (100%). The numbers in the graph represent the percentages of NF1 determined to be nuclear. The pairwise comparisons were between NF1 nuclear fractions. n = 2 experiments.

(legend continued on next page)

overexpression, CRISPR-Cas9-mediated knockin was used to create MCF-7 cells carrying homozygous *NF1-I417M* (M1) mutation or *NF1-R1362Q* (GAP) mutation (Figure S3L). The former cells had normal GAP activity, but their NF1-I417M cannot co-immunoprecipitate ER (Figure 3D). Similar to cells in which NF1 is depleted by shRNA or CRISPR, the *NF1-I417M* (ER binding) mutant cells showed abnormal endocrine responses because cell growth was stimulated by 4-OHT and low levels of E2; in contrast, the *NF1-R1362Q* (GAP) mutant behaved like wild-type cells (Figure 3E). We examined expression of two well-established ERE genes (*TFF1* and *GREB1*) by qPCR (Figure 3F) and found that their expression after E2 stimulation was greatly enhanced by the I417M mutation, which again behaved like full NF1 depletion. In contrast, the *NF1-R1362Q* mutant behaved like wild-type cells showing only a modest increase in gene expression.

While conducting the ER ChIP experiments, we noted a trend that, when NF1 was depleted, more ER was recruited to the chromatin even when the cells were seeded in the presence of vehicle alone (Figure 2D). Consistent with this, expression of *GREB1* and *TFF1* was significantly stronger in vehicle-treated *NF1-I417M* mutant cells than in wild-type and the *NF1-R1362Q* mutant cells (Figure 3F). To further examine these findings in a transcriptome-wide manner, cells were seeded in charcoal-stripped serum-supplemented medium without adding ligand, and RNA-seq experiments were performed (Table S5; Figure 3G). When expression levels of genes (row Z scores from “Log2 transcripts per million” values) in various cell lines were aligned to the list of E2-responsive genes as identified previously (Figure 2A), it was evident that most of the E2-induced genes were more highly expressed and many E2-repressed genes were more strongly repressed in the *NF1-I417M* mutant (right panel, first column, Figure 3G). Essentially, the *NF1-I417M* mutation mimicked E2-stimulation. In contrast, the *NF1-R1362Q* mutant behaved like the wild-type, showing no detectable transcriptional phenotype (middle and right columns in the right panel, Figure 3G). These results clearly illustrate that ER repression and Ras repression are two independent activities of NF1 that are mediated by distinct structural motifs.

Ligand-Stimulated Nuclear Accumulation of Neurofibromin

For transcriptional regulation, neurofibromin must enter the nucleus. Although neurofibromin is mainly cytoplasmic, nuclear neurofibromin has been previously reported in a variety of cell types, including ER⁺ breast cancer cells (Beausoleil et al., 2004; Daston et al., 1992; Koliou et al., 2016; Kweh et al., 2009; Li et al., 2001; Nousiainen et al., 2006; Vandembroucke et al., 2004). In one study, neurofibromin nuclear localization in neuronal cells was shown to be dependent on the Ran GTPase (Koliou et al., 2016). This mechanism may also operate in ER⁺ breast cancer, because neurofibromin co-immunoprecipitated

with Ran in MCF-7 cells (Figure S3C). Leptomycin-B (LMB) blocks CRM1-dependent nuclear export. MCF-7, ZR-75B, and T47D cells were treated with LMB, and cell fractionation was then used to demonstrate that nuclear neurofibromin is increased after nuclear export blockade (Figure 4A). We further investigated whether NF1 nuclear levels are also affected by E2. Nuclear neurofibromin was decreased by E2 but increased by 4-OHT, indicating that ligand-regulated modulation of nuclear levels is an aspect of the co-repressor function of neurofibromin (Figure 4B). 4-OHT-enhanced ER and neurofibromin co-immunoprecipitation can be readily detected in nuclear extracts, and the percentages of co-immunoprecipitated proteins were higher in the nuclear extracts than in whole-cell extracts (Figure 3B). To investigate neurofibromin subcellular localization by microscopy, an immunostaining protocol (Figure 4C) was developed using a set of cell lines with varying degrees of *NF1* expression as controls (Figure S4), which included NF1-KO cells. Two cell lines were then chosen to confirm by microscopy the impact of LMB and ER ligands on nuclear neurofibromin levels (Figures 4D and 4E). Overall these results suggest that, while neurofibromin is mostly cytoplasmic at steady state, it is shuttled in and out of the nucleus, possibly by Ran and CRM-1, in a manner controlled by ER ligand exposure.

Ligand-Dependent Association of Neurofibromin with the ER-ERE Complex

When E2 is present, E2-liganded ER recruits co-activators to the ERE; 4-OHT, in turn, displaces co-activators with co-repressors in the complex. These ligand-mediated actions can be recapitulated by a cell-free assay using HeLa cell nuclear extract (Foulds et al., 2013), which does not have endogenous ER. When purified recombinant ER, biotinylated ERE, and HeLa nuclear extract were combined, the E2-liganded ER-ERE complex could more efficiently pull down the co-activator SRC-1 by Streptavidin beads, while NF1, like the co-repressor HDAC1, was more strongly recruited to the ER-ERE complex in the presence of 4-OHT (Figure 5A). To assess whether neurofibromin is recruited to endogenous EREs in a ligand-dependent manner, we performed ChIP-qPCR using two separate polyclonal neurofibromin antibodies, one of which, Ab-2, was generated by us (Figure S5A), and found that neurofibromin was more efficiently recruited to the EREs of *GREB1* and *TFF1* when 4-OHT, but not E2, was added (Figure S5B). NF1-KO cells were examined as the control to show antibody specificity and neurofibromin dependency (Figure 5B). We then selected the same ten well-documented ERE sites as investigated in Figure 2C, and performed three separate neurofibromin ChIP-qPCR experiments to show that neurofibromin recruitment to these sites was enhanced by 4-OHT; in contrast, no neurofibromin recruitment was detected in other regions (Carroll et al., 2005, 2006) that do not contain an ERE (Figure 5C). Together, these results demonstrate that neurofibromin is an authentic ER co-repressor that localizes

(B) Cells after ligand stimulation were similarly analyzed as in (A), and an immunoblot of treated MCF-7 cells is shown as an example. n = 3 experiments.

(C) Immunofluorescence deconvolution microscopy was performed using our monoclonal NF1 antibody on cells with varying levels of NF1 protein. A single focal plane across the middle of the nucleus (marked by DAPI) is shown.

(D) Cells treated with LMB were examined by microscopy. NF1 nuclear fractions were quantified in the indicated number of cells.

(E) Cells after treatment with ER ligands were similarly examined by microscopy and quantified. Scale bars, 20 μ m.

Data are reported as mean \pm SEM. *p < 0.05, **p < 0.01, ***p < 0.001 by pairwise two-tailed Student's t test. See also Figure S4.




Figure 5. Ligand-Dependent Association of Neurofibromin with the ER-ERE Complex

(A) Ligands were added to the HeLa nuclear extract together with purified ER and biotinylated EREs immobilized onto streptavidin beads. After washing, the proteins bound to EREs with ER were analyzed by immunoblotting (left) and quantified (right). $n = 4$ experiments.

(B) ChIP-qPCR experiment was performed using NF1 antibody Ab-2 to assess NF1 occupancy at the EREs in *GREB1* (region 2, Figure 2C) or *TFF1* (region 1, Figure 2C) in parental or NF1-KO (clone 1) MCF-7 cells treated with 4-OHT. An ERE⁻ region (site 2) (Carroll et al., 2006) was also analyzed as negative control. $n = 2$ experiments.

(C) NF1 occupancy in MCF-7 cells at ten ERE sites in six genes and two negative control regions was assessed by qPCR ($n = 3$ separate ChIP experiments). Data are reported as mean \pm SEM. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ by pairwise two-tailed Student's *t* test. NS, not significant. See also Figure S5.

with ER on an ERE. These findings may explain the recent observation that *NF1* loss (e.g., by loss of heterozygosity) and *ESR1*-activating LBD mutations are mutually exclusive (Sokol et al., 2019), because they both lead to enhanced ER transcriptional activity (Gates et al., 2018; Jeselsohn et al., 2018).

Co-targeting Ras and ER to Treat NF1-Deficient ER⁺ Breast Tumors

The clinical and functional data presented thus far suggest that *NF1*-deficient ER⁺ breast tumors will not be effectively treated with tamoxifen or AI. However, when *NF1* was depleted by either shRNA or CRISPR, the resulting MCF-7 cells were still sensitive to the SERD fulvestrant (Figure S6A). Similar observations were made in *NF1*^{KD} ZR-75B and T47D cells (Figure S6B). However, in *NF1*-silenced MCF-7 cells fulvestrant produced an enhanced compensatory activation of the Ras-Raf-MEK-ERK pathway that may promote cell survival and/or drug resistance despite effective ER inhibition (Figure 6A). Thus, combinatorial targeting of both ER with fulvestrant and the Ras-Raf pathway was assessed to determine if *NF1*-deficient ER⁺ breast cancer can be effectively treated with this strategy. *In vitro*, the combination of Raf and MEK inhibitors, dabrafenib and trametinib, enhanced fulvestrant activity to inhibit cell growth by mostly increasing apoptosis in *NF1*^{KD} MCF-7 and ZR-75B cells (Figure S6C). Immunoblots showed that all drugs inhibited the intended targets (Figure 6A). To develop a clinical protocol, we next investigated whether the dabrafenib and trametinib combination could be replaced by a single MEK inhibitor (MEKi). Selumetinib is a new-

generation MEKi that is less toxic than trametinib due to a shorter half-life and is under consideration by the FDA for the treatment of plexiform neurofibromas in pediatric patients with neurofibromatosis (Dombi et al., 2016; Gross et al., 2018). Our data demonstrate that *in vitro* fulvestrant plus selumetinib also strongly inhibited cell growth and induced apoptosis in *NF1*-silenced MCF-7, ZR-75B, and T47D cells, whereas single-agent exposure did not (Figure 6B). Immunoblotting was performed to confirm that the drugs effectively target ER and ERK activation (Figures 6A and S6D).

In vivo, while tumors from the MCF-7 *NF1*^{KD} xenograft model (+DOX) initially responded to fulvestrant, at later time points these tumors acquired resistance (Figure S6E). Acquired fulvestrant resistance in *NF1*-depleted ER⁺ breast cancer cells has recently also been reported by others (Pearson et al., 2019). We further demonstrated that the fulvestrant-resistant tumor outgrowth in ER⁺ *NF1*^{low} cells *in vivo* can be blocked by dabrafenib and trametinib (Figure S6E). In addition, RNA-seq (Li et al., 2013) and mass spectrometry data (Huang et al., 2017) suggested that a patient-derived xenograft (PDX), WHIM16 (Li et al., 2013), is *NF1* deficient. Immunoblotting confirmed that *NF1* protein levels were barely detectable in WHIM16 (Figure S6F). This PDX line was derived from a patient who died after the development of resistance to multiple lines of endocrine therapies, including fulvestrant and AI.

An initial *in vivo* assessment of dabrafenib-trametinib in WHIM16 suggested activity for Ras-dependent kinase inhibition with fulvestrant over that observed for fulvestrant alone




Figure 6. Co-targeting Ras and ER to Treat NF1-Deficient ER⁺ Breast Cancer

(A) MCF-7 cells were seeded in 10^{-11} M E2 to which fulvestrant (F), dabrafenib (D), trametinib (T), or selumetinib (S) were subsequently added at 10^{-9} , 10^{-6} , 10^{-7} , or 10^{-6} M, respectively. After 6 days, proteins were measured by immunoblotting, and phosphorylation levels (as defined by the levels of the phosphorylated form over total protein) relative to the vehicle-treated cells were set to 1. ND, not detectable.

(B) Top: cells were grown for 6 days in the presence of 10^{-11} M E2 and 10^{-9} M fulvestrant, to which increasing concentration of selumetinib was added. Cell numbers relative to the vehicle control are plotted. $n = 3$ experiments. Bottom: the cells were treated similarly except 10^{-6} M selumetinib was used, and apoptosis was measured 6 days post-treatment. $n = 2$ experiments.

(C) WHIM16 tumors were transplanted into cleared mammary fat pads of mice and later randomized to receive treatment ($n = 15$ per treatment arm) when tumor volumes reached 200 mm³. Tumor volume comparison was performed at 52 days post-treatment by t test between indicated treatment groups, and at the same time, binimetinib (B) was added to the fulvestrant-only arm (marked by the black arrow). After 84 days (gray arrow), treatments were withdrawn from all treatment groups except the group receiving late binimetinib after initial fulvestrant monotherapy.

(D) WHIM16 tumors from each treatment arm at week-4 post-treatment in (C) were analyzed by immunoblot (one representative tumor shown on the left), and the results relative to those treated by the vehicle control were quantified on the right ($n = 3$ tumors).

(E) qPCR was performed to analyze expression levels of indicated genes from the same tumor samples as in (D). mRNA levels in vehicle-treated samples were set to 1.

Data are reported as mean \pm SEM. * $p < 0.05$, ** $p < 0.01$ by t test. NS, not significant.

(Figure S6F), but longer-term exposure was limited by weight loss and diarrhea. We therefore replaced the dabrafenib-trametinib combination with selumetinib-laced chow and conducted a four-arm study to compare single-agent efficacy versus the combination. These data demonstrate that when selumetinib was combined with fulvestrant, efficient and long-term inhibi-

tion/regression of tumor was achieved (Figure 6C) without weight loss (Figure S6G) despite only 50% inhibition of ERK activity. In contrast, selumetinib alone slowed growth but did not induce tumor regression. Western blot confirmed ER degradation by fulvestrant and pERK inhibition by selumetinib (Figure 6D). Selumetinib did not reduce ER phosphorylation at

S118 (Figure S6H), suggesting the MEKi efficacy cannot be easily explained on this basis. Binimetinib, another shorter half-life and better-tolerated MEKi (Trojaniello et al., 2019), also efficiently inhibited tumor growth when combined with fulvestrant (Figures 6C and 6D). Expression of several ERE-containing genes in treated tumors was examined by qPCR. Overall, the lowest level of expression correlated with combination fulvestrant and MEKi exposure (Figure 6E). Although fulvestrant was ineffective as a single-agent, fulvestrant-treated tumors regressed with later addition of binimetinib (Figure 6C, black arrow), mimicking the treatment of ER⁺ NF1^{low} tumors progressing on fulvestrant monotherapy. Furthermore, while selumetinib alone can modestly inhibit tumor growth, growth soon resumed after the treatment was withdrawn; in contrast, no relapse was detected in the fulvestrant + MEKi groups after both agents were withdrawn (Figure 6C, gray arrow).

DISCUSSION

This study presents comprehensive evidence that neurofibromin is a transcriptional co-repressor of ER in ER⁺ breast cancer, independent of its GAP activity. Consequently, when NF1 is depleted through somatic mutation, ER function is enhanced, leading to tamoxifen agonism, estradiol hypersensitivity, AI resistance, and poor outcome. These data suggest that the NF1-depleted ER⁺ breast cancers represent a distinct molecular subset of the disease that will require the development of a new standard of care since tamoxifen is likely contraindicated and AI ineffective.

Our data suggest that, in most cases, complete loss of the NF1 protein is responsible for enhanced ER transcriptional activity and endocrine therapy resistance. Such an NF1-null or NF1^{low} state can be caused by nonsense and frameshift mutations due to nonsense mRNA decay and/or protein instability. Although nonsense and frameshift mutations are detectable by ctDNA sequencing on metastatic patients, NF1 depletion can also be caused by mechanisms not detectable by targeted sequencing. In a study of breast cancer by whole-genome sequencing Nik-Zainal et al. (2016) have described a wide range of structural variations affecting NF1 (tandem duplications, deletions, translocations, and inversions). Furthermore, in METABRIC database NF1 nonsense and frameshift mutations are also usually associated with shallow deletion (Griffith et al., 2018), suggesting biallelic loss-of-function events.

Human and salmon NF1 protein sequences share over 80% identity, which extends well beyond the GAP domain. However, defining a GAP-independent activity in neurofibromin has been difficult because of the broad range of cellular functions influenced by Ras. In hindsight, the commonly used ER⁺ breast cancer cells are ideal for investigating GAP-independent activities of neurofibromin because under standard culture conditions (e.g., in the absence of fulvestrant) growth and ER-dependent transcription operate independently of Ras. This is consistent with the observation that oncogenic mutations in RAS, RAF, MEK, and ERK almost never occur in primary ER⁺ breast cancer. However, Ras-dependent cell survival becomes evident when the ER-dependent growth is inhibited by fulvestrant. Activation of Ras is made more efficient by NF1 loss, and NF1^{low} cells appear to most addicted to this pathway for survival when ER activity is efficiently in-

hibited. *In-vivo*-acquired fulvestrant resistance modeled in the NF1-depleted MCF-7 tumors was efficiently inhibited by dabrafenib + trametinib. WHIM16 represents metastatic ER⁺ breast cancer that already had acquired fulvestrant resistance when the tumor was accrued from the patient. Fulvestrant has little effect on tumor growth unless the MEK is co-inhibited.

As ER⁺ NF1^{low} breast cancer acquires fulvestrant resistance, ER and MEK/ERK crosstalk likely occurs, but the finer details of this mechanism are beyond the scope of this paper. We investigated ER phosphorylation at S118 because this can be directly catalyzed by ERK. However, we could not detect a clear increase in pS118 levels in NF1-KO MCF-7 cells; conversely, in the presence of an MEKi, no decrease in pS118 can be seen in the WHIM16 tumors. Interpretation of WHIM16 experiments is complicated by the presence of fulvestrant, which greatly lowers total ER levels. There is a potential for selective stabilization of the S118-phosphorylated form of ER by other protein kinases, such as GSK3 (Grisouard et al., 2007).

In our experiments, estrogen deprivation therapy is mimicked by incubating cells in charcoal-stripped serum-containing medium, as is customary in the field (Martin et al., 2017). We demonstrate that growth-simulation can be observed in NF1-depleted cells *in vitro* with as little as 10⁻¹² M E2, which parallels E2 levels seen in AI-treated patients. We also present evidence from a neoadjuvant trial that AI resistance can be seen in NF1^{low} tumors defined at the mRNA level.

Our data suggest that most of the 569 NF1^{KD}-unique genes are well-established E2-responsive genes. We speculate that the reason the expression of these genes was not readily detected unless NF1 is depleted is due to the low E2 concentration (10⁻¹¹ M, see the STAR Methods) used to stimulate gene expression in this experiment. This E2 concentration was chosen because it best differentiates the growth of NF1⁺ from NF1^{KD} cells, making it possible to more easily detect the differences in gene expression pattern we display. However, 10⁻¹¹ M E2 is typical for the postmenopausal state and therefore may be too low to affect expression of some E2-responsive genes, until a co-repressor (NF1) is depleted. Of interest, the 569 genes also include genes responsible for EMT, a phenomenon that has also been seen in other resistance settings, i.e., the presence of ER mutants (Jeselsohn et al., 2018) and ER fusions (Lei et al., 2018).

The expression of the rest of the “NF1 knockdown only” genes that do not harbor an ERE is harder to decipher, and many of these genes appear in more than one functional category. Ras does not directly regulate gene expression, so gene expression influenced by Ras activity is likely to be context dependent. Of the 12 “K-RAS signaling up genes,” three (*ID2*, *SERPINA3*, and *PCP4*) are also defined as “estrogen response late,” so only the remaining nine genes may be controlled by Ras activation.

In experimental systems, fulvestrant resistance can be efficiently inhibited by further targeting MEK in both the MCF-7 and WHIM16 mouse models. These results strongly suggest that activation of the Ras-Raf pathway is the major driver for fulvestrant resistance in NF1-deficient ER⁺ breast cancer. On this basis, there is adequate clinical rationale to activate a clinical trial of an MEKi and an SERD specifically in patients with evidence for a loss of NF1 due to somatic mutation. Of note, WHIM16 regression was achieved with a well-tolerated dose of short half-life

MEKi that inhibited ERK signaling by only 50%. This suggests that long-term exposures to lower-dose MEKi necessary for management of advanced breast cancer will be feasible, and the pediatric experience of neurofibromatosis-related plexiform neurofibroma treatment is relevant here (Gross et al., 2018). We note that a fulvestrant and selumetinib combination failed in a randomized phase 2 trial (23 patients per arm) in unselected postmenopausal patients (Zaman et al., 2015). This study does not exclude a benefit in ER⁺ NF1^{low} tumors, however, as it is likely that less than five patients harbored NF1^{low} tumors in this study. Since the prevalence of ER⁺ advanced breast cancer in the USA exceeds 100,000 patients, the ctDNA-based evidence suggests at least 7,000 to 10,000 of these individuals will have an NF1^{low} tumor in which an SERD/MEKi combination could be beneficial.

Further research may connect the ER hyperactivity induced by NF1 depletion to other paradoxical or unexplained observations in ER⁺ breast cancer, for example, regression of endocrine therapy-resistant ER⁺ breast cancer with estradiol treatment (Ellis et al., 2009). In addition, the role of neurofibromin as an ER co-repressor may underlie the sexually dimorphic features of neurofibromatosis, including tumor growth and the preponderance of optic chiasm gliomas during female puberty (Diggs-Andrews et al., 2014).

SUPPORTING CITATIONS

Berto et al., 2018; Borromeo et al., 2016; de Cremoux et al., 2004; Ding et al., 2019; Glont et al., 2019; Harrod et al., 2017; Karmakar et al., 2013; Kininis et al., 2009; Lin et al., 2004; Paschou and Doxakis, 2012; Wang et al., 2018; Won Jeong et al., 2012; Zheng et al., 2005.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- LEAD CONTACT AND MATERIALS AVAILABILITY
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
 - Cell Lines
 - Animals
- METHOD DETAILS
 - Chemicals
 - Plasmids
 - Generation of *NF1* Point Mutation Knock-in (KI) Cells Using CRISPR-Cas9
 - Assays for Cell Growth and Apoptosis
 - Generation of NF1 Antibodies
 - Immunoprecipitation (IP)
 - Immunoblotting
 - RNA-seq
 - ChIP
 - qPCR
 - ERE-Luciferase Reporter Assay
 - The Mammalian Two-Hybrid Assay
 - ER and NF1-M2/GAP *In Vitro* Binding Assay
 - Cell Fractionation

- Immunofluorescence Deconvolution Microscopy
- ERE Pull-down Using HeLa Cell Nuclear Extract
- QUANTIFICATION AND STATISTICAL ANALYSIS
 - *NF1* Mutation Frequency in Patients
 - Patient Proliferation Status after Aromatase Inhibitor (AI) Treatments
 - *NF1* Expression Level Analysis in Patients
 - Protein Levels Correlation Analysis
- DATA AND CODE AVAILABILITY

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at <https://doi.org/10.1016/j.ccell.2020.02.003>.

ACKNOWLEDGMENTS

We thank our colleagues for providing valuable resources and advice: Bert O'Malley, Anna Malovannaya, Jun Qin, Daniel Yan, Khushboo Shah, Jianhui Yao, Svasti Haricharan, Angela D. Wilkins, Dominic Esposito, Gary Chamness, Laura Smithson, David Gutmann, Ching-Yi Chang, and Donald McDonnell. This project was assisted by the following core facilities in the Dan L. Duncan Comprehensive Cancer Center: Cell-Based Assay Screening Service, Cytometry and Cell Sorting, Biostatistics and Informatics Shared Resource, Integrated Microscopy Core, Genomic and RNA Profiling Core, and the Protein and Monoclonal Antibody Production Shared Resource, which are all supported by a P30 Cancer Center Support Grant from NCI (CA125123). The Integrated Microscopy Core is also supported by grants from NIH (DK56338), CPRIT (RP150578 and RP170719), and the John S. Dunn Gulf Coast Consortium for Chemical Genomics. The Cell Sorting Core was also supported by P30A1036211 and S10RR024547. B.C. was supported by an ASCO Gianni Bonadonna Research Fellowship, and J.T.L. was supported by T32GM008129 and T32CA203690 from NIH. C.E.F. and Y.C. were supported by the Adrienne Helis Malvin Medical Research Foundation through its direct engagement in the continuous active conduct of medical research in conjunction with BCM. E.C.C. was supported by The Susan G. Komen Foundation (SAC150059), DOD (W81XWH-16-1-0538 and W81XWH-19-1-0527), Nancy Owens Memorial Foundation, NIH (R21CA185516 and P50CA186784), William and Ella Owens Foundation, and CPRIT (RP180844). M.J.E. is a CPRIT Scholar in cancer research supported by a CPRIT Established Investigator Recruitment Award RR140033 and is a McNair Scholar supported by the McNair Foundation. This research was also supported by NIH/NCI grants R01 CA095614 and U54CA233223 awarded to M.J.E. and by Susan G. Komen for the Cure Promise Grant PG12220321.

AUTHOR CONTRIBUTIONS

Z.Y.Z., M.J.E., and E.C.C. are responsible for the design, analysis, and overall execution of the experiments. Z.Y.Z., M.A., J.C., P.S., J.P., J.T.L., N.-C.N., P.L., Y.C., J.L., X.-H.D., B.C., H.K., W.S., B.-J.K., J.S., S.S., D.W.C., C.-Q.Z., X.C., K.C.B., R.B.L., M.N.S., X.H.-F.Z., S.V., W.L., B.Z., C.E.F., and S.G.H. conducted the experiments and/or data analysis. The paper was mostly written by Z.Y.Z., M.J.E., and E.C.C. and reviewed by all authors.

DECLARATION OF INTERESTS

K.C.B. and R.B.L. are stockholders and employees of Guardant Health, Inc., C.E.F. discloses an equity position in Coactigon, Inc., and M.J.E. received consulting fees from Abbvie, Sermonix, Pfizer, AstraZeneca, Celgene, NanoString, Puma, and Novartis, and is an equity stockholder, consultant, and Board Director member of BioClassifier, and inventor on a patent for the Breast PAM50 assay.

Received: May 29, 2019
 Revised: November 15, 2019
 Accepted: February 6, 2020
 Published: March 5, 2020

REFERENCES

- Anbalagan, M., and Rowan, B.G. (2015). Estrogen receptor alpha phosphorylation and its functional impact in human breast cancer. *Mol. Cell Endocrinol.* *418* (Pt 3), 264–272.
- Ballester, R., Marchuk, D., Boguski, M., Saulino, A., Letcher, R., Wigler, M., and Collins, F. (1990). The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. *Cell* *63*, 851–859.
- Beausoleil, S.A., Jedrychowski, M., Schwartz, D., Elias, J.E., Villen, J., Li, J., Cohn, M.A., Cantley, L.C., and Gygi, S.P. (2004). Large-scale characterization of HeLa cell nuclear phosphoproteins. *Proc. Natl. Acad. Sci. U S A* *101*, 12130–12135.
- Berto, M., Jean, V., Zwart, W., and Picard, D. (2018). ERalpha activity depends on interaction and target site corecruitment with phosphorylated CREB1. *Life Sci. Alliance* *1*, e201800055.
- Bertucci, F., Ng, C.K.Y., Patsouris, A., Droin, N., Piscuoglio, S., Carbuccia, N., Soria, J.C., Dien, A.T., Adnani, Y., Kamal, M., et al. (2019). Genomic characterization of metastatic breast cancers. *Nature* *569*, 560–564.
- Bollag, G., McCormick, F., and Clark, R. (1993). Characterization of full-length neurofibromin: tubulin inhibits Ras GAP activity. *EMBO J.* *12*, 1923–1927.
- Borromeo, M.D., Savage, T.K., Kollipara, R.K., He, M., Augustyn, A., Osborne, J.K., Girard, L., Minna, J.D., Gazdar, A.F., Cobb, M.H., and Johnson, J.E. (2016). ASCL1 and NEUROD1 reveal heterogeneity in pulmonary neuroendocrine tumors and regulate distinct genetic programs. *Cell Rep.* *16*, 1259–1272.
- Carroll, J.S., Liu, X.S., Brodsky, A.S., Li, W., Meyer, C.A., Szary, A.J., Eeckhoutte, J., Shao, W., Hestermann, E.V., Geistlinger, T.R., et al. (2005). Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. *Cell* *122*, 33–43.
- Carroll, J.S., Meyer, C.A., Song, J., Li, W., Geistlinger, T.R., Eeckhoutte, J., Brodsky, A.S., Keeton, E.K., Fertuck, K.C., Hall, G.F., et al. (2006). Genome-wide analysis of estrogen receptor binding sites. *Nat. Genet.* *38*, 1289–1297.
- Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A., Jacobsen, A., Byrne, C.J., Heuer, M.L., Larsson, E., et al. (2012). The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* *2*, 401–404.
- Chang, C., Norris, J.D., Gron, H., Paige, L.A., Hamilton, P.T., Kenan, D.J., Fowlkes, D., and McDonnell, D.P. (1999). Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors alpha and beta. *Mol. Cell Biol.* *19*, 8226–8239.
- Chang, E.C., Barr, M., Wang, Y., Jung, V., Xu, H., and Wigler, H.M. (1994). Cooperative interaction of *S. pombe* proteins required for mating and morphogenesis. *Cell* *79*, 131–141.
- Chen, X., Xu, H., Yuan, P., Fang, F., Huss, M., Vega, V.B., Wong, E., Orlov, Y.L., Zhang, W., Jiang, J., et al. (2008). Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. *Cell* *133*, 1106–1117.
- Cheng, C.M., Li, H., Gasman, S., Huang, J., Schiff, R., and Chang, E.C. (2011). Compartmentalized Ras proteins transform NIH 3T3 cells with different efficiencies. *Mol. Cell Biol.* *31*, 983–997.
- Ciriello, G., Gatza, M.L., Beck, A.H., Wilkerson, M.D., Rhie, S.K., Pastore, A., Zhang, H., McLellan, M., Yau, C., Kandoth, C., et al. (2015). Comprehensive molecular portraits of invasive lobular breast cancer. *Cell* *163*, 506–519.
- Curtis, C., Shah, S.P., Chin, S.F., Turashvili, G., Rueda, O.M., Dunning, M.J., Speed, D., Lynch, A.G., Samarajiwa, S., Yuan, Y., et al. (2012). The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature* *486*, 346–352.
- Daston, M.M., Scrabble, H., Nordlund, M., Sturbaum, A.K., Nissen, L.M., and Ratner, N. (1992). The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, Schwann cells, and oligodendrocytes. *Neuron* *8*, 415–428.
- de Cremoux, P., Bieche, I., Tran-Perennou, C., Vignaud, S., Boudou, E., Asselain, B., Lidereau, R., Magdelenat, H., Becette, V., Sigal-Zafrani, B., and Spyrtos, F. (2004). Inter-laboratory quality control for hormone-dependent gene expression in human breast tumors using real-time reverse transcription-polymerase chain reaction. *Endocr. Relat. Cancer* *11*, 489–495.
- Diggs-Andrews, K.A., Brown, J.A., Gianino, S.M., Rubin, J.B., Wozniak, D.F., and Gutmann, D.H. (2014). Sex is a major determinant of neuronal dysfunction in neurofibromatosis type 1. *Ann. Neurol.* *75*, 309–316.
- Ding, Y., Li, N., Dong, B., Guo, W., Wei, H., Chen, Q., Yuan, H., Han, Y., Chang, H., Kan, S., et al. (2019). Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer. *J. Clin. Invest.* *129*, 759–773.
- Dischinger, P.S., Tovar, E.A., Essenburg, C.J., Madaj, Z.B., Gardner, E.E., Callaghan, M.E., Turner, A.N., Challa, A.K., Kempston, T., Eagleson, B., et al. (2018). NF1 deficiency correlates with estrogen receptor signaling and diminished survival in breast cancer. *NPJ Breast Cancer* *4*, 29.
- Dombi, E., Baldwin, A., Marcus, L.J., Fisher, M.J., Weiss, B., Kim, A., Whitcomb, P., Martin, S., Aschbacher-Smith, L.E., Rizvi, T.A., et al. (2016). Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. *N. Engl. J. Med.* *375*, 2550–2560.
- Ellis, M.J., Gao, F., Dehdashti, F., Jeffe, D.B., Marcom, P.K., Carey, L.A., Dickler, M.N., Silverman, P., Fleming, G.F., Kommareddy, A., et al. (2009). Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. *JAMA* *302*, 774–780.
- Ellis, M.J., Suman, V.J., Hoog, J., Goncalves, R., Sanati, S., Creighton, C.J., DeSchryver, K., Crouch, E., Brink, A., Watson, M., et al. (2017). Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American College of Surgeons Oncology Group Z1031 trial (Alliance). *J. Clin. Oncol.* *35*, 1061–1069.
- Ellis, M.J., Suman, V.J., Hoog, J., Lin, L., Snider, J., Prat, A., Parker, J.S., Luo, J., DeSchryver, K., Allred, D.C., et al. (2011). Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype—ACOSOG Z1031. *J. Clin. Oncol.* *29*, 2342–2349.
- Feng, Q., and O'Malley, B.W. (2014). Nuclear receptor modulation—role of coregulators in selective estrogen receptor modulator (SERM) actions. *Steroids* *90*, 39–43.
- Foulds, C.E., Feng, Q., Ding, C., Bailey, S., Hunsaker, T.L., Malovannaya, A., Hamilton, R.A., Gates, L.A., Zhang, Z., Li, C., et al. (2013). Proteomic analysis of coregulators bound to ERalpha on DNA and nucleosomes reveals coregulator dynamics. *Mol. Cell* *51*, 185–199.
- Gao, J., Aksoy, B.A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S.O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013). Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci. Signal.* *6*, pii1.
- Gates, L.A., Gu, G., Chen, Y., Rohira, A.D., Lei, J.T., Hamilton, R.A., Yu, Y., Lonard, D.M., Wang, J., Wang, S.P., et al. (2018). Proteomic profiling identifies key coactivators utilized by mutant ERalpha proteins as potential new therapeutic targets. *Oncogene* *37*, 4581–4598.
- Glont, S.E., Chernukhin, I., and Carroll, J.S. (2019). Comprehensive genomic analysis reveals that the pioneering function of FOXA1 is independent of hormonal signaling. *Cell Rep.* *26*, 2558–2565.e3.
- Griffith, O.L., Spies, N.C., Anurag, M., Griffith, M., Luo, J., Tu, D., Yeo, B., Kunisaki, J., Miller, C.A., Krysiak, K., et al. (2018). The prognostic effects of somatic mutations in ER-positive breast cancer. *Nat. Commun.* *9*, 3476.
- Grisouard, J., Medunjanin, S., Hermani, A., Shukla, A., and Mayer, D. (2007). Glycogen synthase kinase-3 protects estrogen receptor alpha from proteasomal degradation and is required for full transcriptional activity of the receptor. *Mol. Endocrinol.* *21*, 2427–2439.
- Gross, A.M., Wolters, P., Baldwin, A., Dombi, E., Fisher, M.J., Weiss, B.D., Kim, A.R., Blakeley, J.O.N., Whitcomb, P., Holmblad, M., et al. (2018). SPRINT: phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN). *J. Clin. Oncol.* *36*, 10503.

- Hall, J.M., and McDonnell, D.P. (1999). The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. *Endocrinology* 140, 5566–5578.
- Harrod, A., Fulton, J., Nguyen, V.T.M., Periyasamy, M., Ramos-Garcia, L., Lai, C.F., Metodieva, G., de Giorgio, A., Williams, R.L., Santos, D.B., et al. (2017). Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer. *Oncogene* 36, 2286–2296.
- He, H., Sinha, I., Fan, R., Haldosen, L.A., Yan, F., Zhao, C., and Dahlman-Wright, K. (2018). c-Jun/AP-1 overexpression reprograms ERalpha signaling related to tamoxifen response in ERalpha-positive breast cancer. *Oncogene* 37, 2586–2600.
- Heldring, N., Pawson, T., McDonnell, D., Treuter, E., Gustafsson, J.A., and Pike, A.C. (2007). Structural insights into corepressor recognition by antagonist-bound estrogen receptors. *J. Biol. Chem.* 282, 10449–10455.
- Hu, X., and Lazar, M.A. (1999). The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors. *Nature* 402, 93–96.
- Huang, H.J., Norris, J.D., and McDonnell, D.P. (2002). Identification of a negative regulatory surface within estrogen receptor alpha provides evidence in support of a role for corepressors in regulating cellular responses to agonists and antagonists. *Mol. Endocrinol.* 16, 1778–1792.
- Huang, K.L., Li, S., Mertins, P., Cao, S., Gunawardena, H.P., Ruggles, K.V., Mani, D.R., Clauser, K.R., Tanioka, M., Usary, J., et al. (2017). Proteogenomic integration reveals therapeutic targets in breast cancer xenografts. *Nat. Commun.* 8, 14864.
- Jeselsohn, R., Bergholz, J.S., Pun, M., Cornwell, M., Liu, W., Nardone, A., Xiao, T., Li, W., Qiu, X., Buchwalter, G., et al. (2018). Allele-specific chromatin recruitment and therapeutic vulnerabilities of ESR1 activating mutations. *Cancer Cell* 33, 173–186.e5.
- Karmakar, S., Jin, Y., and Nagaich, A.K. (2013). Interaction of glucocorticoid receptor (GR) with estrogen receptor (ER) alpha and activator protein 1 (AP1) in dexamethasone-mediated interference of ERalpha activity. *J. Biol. Chem.* 288, 24020–24034.
- Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., et al. (1995). Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. *Science* 270, 1491–1494.
- Kininis, M., Isaacs, G.D., Core, L.J., Hah, N., and Kraus, W.L. (2009). Postrecruitment regulation of RNA polymerase II directs rapid signaling responses at the promoters of estrogen target genes. *Mol. Cell. Biol.* 29, 1123–1133.
- Koliou, X., Fedonidis, C., Kalpachidou, T., and Mangoura, D. (2016). Nuclear import mechanism of neurofibromin for localization on the spindle and function in chromosome congression. *J. Neurochem.* 136, 78–91.
- Kweh, F., Zheng, M., Kurenova, E., Wallace, M., Golubovskaya, V., and Cance, W.G. (2009). Neurofibromin physically interacts with the N-terminal domain of focal adhesion kinase. *Mol. Carcinog.* 48, 1005–1017.
- Langmead, B., and Salzberg, S.L. (2012). Fast gapped-read alignment with Bowtie 2. *Nat. Methods* 9, 357–359.
- Lanman, R.B., Mortimer, S.A., Zill, O.A., Sebisano, D., Lopez, R., Blau, S., Collisson, E.A., Divers, S.G., Hoon, D.S., Kopetz, E.S., et al. (2015). Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. *PLoS One* 10, e0140712.
- Lanz, R.B., Bulynko, Y., Malovannaya, A., Labhart, P., Wang, L., Li, W., Qin, J., Harper, M., and O'Malley, B.W. (2010). Global characterization of transcriptional impact of the SRC-3 coregulator. *Mol. Endocrinol.* 24, 859–872.
- Lei, J.T., Shao, J., Zhang, J., Iglesia, M., Chan, D.W., Cao, J., Anurag, M., Singh, P., He, X., Kosaka, Y., et al. (2018). Functional annotation of ESR1 gene fusions in estrogen receptor-positive breast cancer. *Cell Rep.* 24, 1434–1444.e7.
- Leng, N., Dawson, J.A., Thomson, J.A., Ruotti, V., Rissman, A.I., Smits, B.M., Haag, J.D., Gould, M.N., Stewart, R.M., and Kendziorski, C. (2013). EBSeq: an empirical Bayes hierarchical model for inference in RNA-seq experiments. *Bioinformatics* 29, 1035–1043.
- Li, B., and Dewey, C.N. (2011). RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. *BMC Bioinformatics* 12, 323.
- Li, C., Cheng, Y., Gutmann, D.A., and Mangoura, D. (2001). Differential localization of the neurofibromatosis 1 (NF1) gene product, neurofibromin, with the F-actin or microtubule cytoskeleton during differentiation of telencephalic neurons. *Brain Res. Dev. Brain Res.* 130, 231–248.
- Li, S., Shen, D., Shao, J., Crowder, R., Liu, W., Prat, A., He, X., Liu, S., Hoog, J., Lu, C., et al. (2013). Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. *Cell Rep.* 4, 1116–1130.
- Lin, C.Y., Strom, A., Vega, V.B., Kong, S.L., Yeo, A.L., Thomsen, J.S., Chan, W.C., Doray, B., Bangarusamy, D.K., Ramasamy, A., et al. (2004). Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells. *Genome Biol.* 5, R66.
- Madanika, S.A., Bergner, A., Ye, X., and Blakeley, J.O. (2012). Increased risk of breast cancer in women with NF1. *Am. J. Med. Genet. A* 158A, 3056–3060.
- Maertens, O., and Cichowski, K. (2014). An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer. *Adv. Biol. Regul.* 55, 1–14.
- Martin, L.A., Ribas, R., Simigdala, N., Schuster, E., Pancholi, S., Tenev, T., Gellert, P., Buluwela, L., Harrod, A., Thornhill, A., et al. (2017). Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance. *Nat. Commun.* 8, 1865.
- Meric-Bernstam, F., Frampton, G.M., Ferrer-Lozano, J., Yelensky, R., Perez-Fidalgo, J.A., Wang, Y., Palmer, G.A., Ross, J.S., Miller, V.A., Su, X., et al. (2014). Concordance of genomic alterations between primary and recurrent breast cancer. *Mol. Cancer Ther.* 13, 1382–1389.
- Mertins, P., Mani, D.R., Ruggles, K.V., Gillette, M.A., Clauser, K.R., Wang, P., Wang, X., Qiao, J.W., Cao, S., Petralia, F., et al. (2016). Proteogenomics connects somatic mutations to signalling in breast cancer. *Nature* 534, 55–62.
- Neve, R.M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F.L., Fevr, T., Clark, L., Bayani, N., Coppe, J.P., Tong, F., et al. (2006). A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. *Cancer Cell* 10, 515–527.
- Nik-Zainal, S., Davies, H., Staaf, J., Ramakrishna, M., Glodzik, D., Zou, X., Martincorena, I., Alexandrov, L.B., Martin, S., Wedge, D.C., et al. (2016). Landscape of somatic mutations in 560 breast cancer whole-genome sequences. *Nature* 534, 47–54.
- Nousiainen, M., Sillje, H.H., Sauer, G., Nigg, E.A., and Korner, R. (2006). Phosphoproteome analysis of the human mitotic spindle. *Proc. Natl. Acad. Sci. U S A* 103, 5391–5396.
- Ogata, H., Sato, H., Takatsuka, J., and De Luca, L.M. (2001). Human breast cancer MDA-MB-231 cells fail to express the neurofibromin protein, lack its type I mRNA isoform and show accumulation of P-MAPK and activated Ras. *Cancer Lett.* 172, 159–164.
- Paschou, M., and Doxakis, E. (2012). Neurofibromin 1 is a miRNA target in neurons. *PLoS One* 7, e46773.
- Pearson, A., Proszek, P.Z., Pascual, J., Fribbens, C., Shamsheer, M.K., Kingston, B., O'Leary, B., Herrera-Abreu, M.T., Cutts, R.J., Garcia-Murillas, I., et al. (2019). Inactivating NF1 mutations are enriched in advanced breast cancer and contribute to endocrine therapy resistance. *Clin. Cancer Res.* <https://doi.org/10.1158/1078-0432.CCR-18-4044>.
- Pereira, B., Chin, S.F., Rueda, O.M., Volland, H.K., Provenzano, E., Bardwell, H.A., Pugh, M., Jones, L., Russell, R., Sammut, S.J., et al. (2016). The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptional landscapes. *Nat. Commun.* 7, 11479.
- Ran, F.A., Hsu, P.D., Wright, J., Agarwala, V., Scott, D.A., and Zhang, F. (2013). Genome engineering using the CRISPR-Cas9 system. *Nat. Protoc.* 8, 2281–2308.
- Ratner, N., and Miller, S.J. (2015). A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. *Nat. Rev. Cancer* 15, 290–301.

- Razavi, P., Chang, M.T., Xu, G., Bandlamudi, C., Ross, D.S., Vasan, N., Cai, Y., Bielski, C.M., Donoghue, M.T.A., Jonsson, P., et al. (2018). The genomic landscape of endocrine-resistant advanced breast cancers. *Cancer Cell* **34**, 427–438.e6.
- Rhodes, D.R., Kalyana-Sundaram, S., Mahavisno, V., Varambally, R., Yu, J., Briggs, B.B., Barrette, T.R., Anstet, M.J., Kincaid-Beal, C., Kulkarni, P., et al. (2007). OncoPrint 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. *Neoplasia* **9**, 166–180.
- Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015). Improved overall survival in melanoma with combined dabrafenib and trametinib. *N. Engl. J. Med.* **372**, 30–39.
- Robinson, S.P., and Jordan, V.C. (1989). Antiestrogenic action of toremifene on hormone-dependent, -independent, and heterogeneous breast tumor growth in the athymic mouse. *Cancer Res.* **49**, 1758–1762.
- Rogers, S.A., Llewellyn, L., Wigham, T., and Sweeney, G.E. (2000). Cloning of the Atlantic salmon (*Salmo salar*) estrogen receptor-alpha gene. *Comp. Biochem. Physiol. B Biochem. Mol. Biol.* **125**, 379–385.
- Salemis, N.S., Nakos, G., Sambaziotis, D., and Gourgiotis, S. (2010). Breast cancer associated with type 1 neurofibromatosis. *Breast Cancer* **17**, 306–309.
- Schneider, C.A., Rasband, W.S., and Eliceiri, K.W. (2012). NIH Image to ImageJ: 25 years of image analysis. *Nat. Methods* **9**, 671–675.
- Shang, Y., Hu, X., DiRenzo, J., Lazar, M.A., and Brown, M. (2000). Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. *Cell* **103**, 843–852.
- Sharif, S., Moran, A., Huson, S.M., Iddenden, R., Shenton, A., Howard, E., and Evans, D.G. (2007). Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening. *J. Med. Genet.* **44**, 481–484.
- Shiau, A.K., Barstad, D., Loria, P.M., Cheng, L., Kushner, P.J., Agard, D.A., and Greene, G.L. (1998). The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. *Cell* **95**, 927–937.
- Skidmore, Z.L., Wagner, A.H., Lesurf, R., Campbell, K.M., Kunisaki, J., Griffith, O.L., and Griffith, M. (2016). GenVisR: genomic visualizations in R. *Bioinformatics* **32**, 3012–3014.
- Sokol, E.S., Feng, Y.X., Jin, D.X., Basudan, A., Lee, A.V., Atkinson, J.M., Chen, J., Stephens, P.J., Frampton, G.M., Gupta, P.B., et al. (2019). Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer. *Ann. Oncol.* **30**, 115–123.
- Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., and Mesirov, J.P. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. U S A* **102**, 15545–15550.
- Suzuki, K., Bose, P., Leong-Quong, R.Y., Fujita, D.J., and Riabowol, K. (2010). REAP: a two minute cell fractionation method. *BMC Res. Notes* **3**, 294.
- TCGA (2012). Comprehensive molecular portraits of human breast tumours. *Nature* **490**, 61–70.
- Trojaniello, C., Festino, L., Vanella, V., and Ascierto, P.A. (2019). Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations. *Expert Rev. Clin. Pharmacol.* **12**, 259–266.
- Vandenbroucke, I., Van Oostveldt, P., Coene, E., De Paepe, A., and Messiaen, L. (2004). Neurofibromin is actively transported to the nucleus. *FEBS Lett.* **560**, 98–102.
- Vasaikar, S.V., Straub, P., Wang, J., and Zhang, B. (2018). LinkedOmics: analyzing multi-omics data within and across 32 cancer types. *Nucleic Acids Res.* **46**, D956–D963.
- Wang, H., Liu, C., Liu, X., Wang, M., Wu, D., Gao, J., Su, P., Nakahata, T., Zhou, W., Xu, Y., et al. (2018). MEIS1 regulates hemogenic endothelial generation, megakaryopoiesis, and thrombopoiesis in human pluripotent stem cells by targeting TAL1 and FLI1. *Stem Cell Reports* **10**, 447–460.
- Wang, J., Ma, Z., Carr, S.A., Mertins, P., Zhang, H., Zhang, Z., Chan, D.W., Ellis, M.J., Townsend, R.R., Smith, R.D., et al. (2017a). Proteome profiling outperforms transcriptome profiling for coexpression based gene function prediction. *Mol. Cell Proteomics* **16**, 121–134.
- Wang, J., Vasaikar, S., Shi, Z., Greer, M., and Zhang, B. (2017b). WebGestalt 2017: a more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit. *Nucleic Acids Res.* **45**, W130–W137.
- Wang, Y., Lonard, D.M., Yu, Y., Chow, D.C., Palzkill, T.G., Wang, J., Qi, R., Matzuk, A.J., Song, X., Madoux, F., et al. (2014). Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1. *Cancer Res.* **74**, 1506–1517.
- Wilkins, A.D., Bachman, B.J., Erdin, S., and Lichtarge, O. (2012). The use of evolutionary patterns in protein annotation. *Curr. Opin. Struct. Biol.* **22**, 316–325.
- Won Jeong, K., Chodankar, R., Purcell, D.J., Bittencourt, D., and Stallcup, M.R. (2012). Gene-specific patterns of coregulator requirements by estrogen receptor-alpha in breast cancer cells. *Mol. Endocrinol.* **26**, 955–966.
- Yap, Y.S., McPherson, J.R., Ong, C.K., Rozen, S.G., Teh, B.T., Lee, A.S., and Callen, D.F. (2014). The NF1 gene revisited—from bench to bedside. *Oncotarget* **5**, 5873–5892.
- Yates, L.R., Knappskog, S., Wedge, D., Farmery, J.H.R., Gonzalez, S., Martincorena, I., Alexandrov, L.B., Van Loo, P., Haugland, H.K., Lilleng, P.K., et al. (2017). Genomic evolution of breast cancer metastasis and relapse. *Cancer Cell* **32**, 169–184.e7.
- Zaman, K., Winterhalder, R., Mamot, C., Hasler-Strub, U., Rochlitz, C., Mueller, A., Berset, C., Wiliiders, H., Perey, L., Rudolf, C.B., et al. (2015). Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08. *Eur. J. Cancer* **51**, 1212–1220.
- Zheng, Z.Y., Bay, B.H., Aw, S.E., and Lin, V.C. (2005). A novel antiestrogenic mechanism in progesterone receptor-transfected breast cancer cells. *J. Biol. Chem.* **280**, 17480–17487.
- Zheng, Z.Y., Cheng, C.M., Fu, X.R., Chen, L.Y., Xu, L., Terrillon, S., Wong, S.T., Bar-Sagi, D., Songyang, Z., and Chang, E.C. (2012). CHMP6 and VPS4A mediate the recycling of Ras to the plasma membrane to promote growth factor signaling. *Oncogene* **31**, 4630–4638.
- Zheng, Z.Y., Tian, L., Bu, W., Fan, C., Gao, X., Wang, H., Liao, Y.H., Li, Y., Lewis, M.T., Edwards, D., et al. (2015). Wild-type N-Ras, overexpressed in basal-like breast cancer, promotes tumor formation by inducing IL-8 secretion via JAK2 activation. *Cell Rep.* **12**, 511–524.
- Zill, O.A., Banks, K.C., Fairclough, S.R., Mortimer, S.A., Vowles, J.V., Mokhtari, R., Gandara, D.R., Mack, P.C., Odegaard, J.I., Nagy, R.J., et al. (2018). The landscape of actionable genomic alterations in cell-free circulating tumor DNA from 21,807 advanced cancer patients. *Clin. Cancer Res.* **24**, 3528–3538.
- Zubairy, S., and Oesterreich, S. (2005). Estrogen-repressed genes—key mediators of estrogen action? *Breast Cancer Res.* **7**, 163–164.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Mouse monoclonal NF1 (against aa2471-2839, 1:200)	This study	N/A
Rabbit polyclonal NF1 (against aa2471-2839)	This study	N/A
NF1 (against aa2760-2839)	Bethyl Laboratories	Cat#A300-140A; RRID:AB_2149790
NF1 (against N-terminus, 1:500)	Cell Signaling Technology	Cat#14623; RRID:AB_2798543
ER- α (1:500)	Cell Signaling Technology	Cat#8644; RRID:AB_2617128
ER- α (HC-20)	Santa Cruz Biotechnology	Cat#sc-543; RRID: AB_631471
ER- α (F-10, ChIP grade, 1:5000 for Western blots)	Santa Cruz Biotechnology	Cat# sc-8002X; RRID:AB_627558
phospho-ER- α (Ser118, 1:500)	Millipore-Sigma	Cat#05-793; RRID:AB_310004
ERK1/2 (1:500)	Cell Signaling Technology	Cat#9102; RRID:AB_330744
Phospho-ERK1/2 (Thr202/Tyr204, 1:500)	Cell Signaling Technology	Cat#9101; RRID:AB_331646
AKT (1:500)	Cell Signaling Technology	Cat#4691; RRID:AB_915783
Phospho-AKT (Ser473, 1:500)	Cell Signaling Technology	Cat#4060; RRID:AB_2315049
His-tag (1:1000)	Cell Signaling Technology	Cat#2365; RRID:AB_2115720
Ran (1:1000)	Cell Signaling Technology	Cat#4462; RRID:AB_2284873
Histone-3 (1:1000)	Cell Signaling Technology	Cat#4499; RRID:AB_10544537
DNA-PKcs (1:1000)	Cell Signaling Technology	Cat#4602; RRID:AB_10692482
K48-linkage specific polyubiquitin (1:1000)	Cell Signaling Technology	Cat#8081; RRID:AB_10859893
α / β -tubulin (1:2000)	Cell Signaling Technology	Cat#2148; RRID:AB_2288042
α -tubulin (1:10,000)	Santa Cruz Biotechnology	Cat#sc-5286; RRID:AB_628411
p120/RasGAP (1:1000)	Santa Cruz Biotechnology	Cat#sc-63; RRID:AB_628206
SRC-1 (1:1,000)	Santa Cruz Biotechnology	Cat#sc-6096; RRID:AB_661355
HDAC1 (1:1,000)	Santa Cruz Biotechnology	Cat#sc-81598; RRID:AB_2118083
GAPDH (1:10,000)	Santa Cruz Biotechnology	Cat#sc-32233; RRID:AB_627679
Normal Mouse IgG	Santa Cruz Biotechnology	Cat# sc-2025; RRID:AB_628411
Normal Rabbit IgG	Millipore-Sigma	Cat# 12-370; RRID:AB_145841
Bacterial and Virus Strains		
BL21 (DE3)	Agilent	Cat#200131
Biological Samples		
Patient-derived xenografts (PDX) WHIM16	(Li et al., 2013)	N/A
Chemicals, Peptides, and Recombinant Proteins		
17 β -estradiol (E2)	Sigma-Aldrich	Cat#E8875
Cyclodextran-encapsulated “water-soluble” E2	Sigma-Aldrich	Cat#E4389
(Z)-4-hydroxytamoxifen (4-OHT)	Sigma-Aldrich	Cat#H7904
Doxycycline (DOX)	Sigma-Aldrich	Cat#D9891
Human epidermal growth factor (EGF)	Sigma-Aldrich	Cat#E4127
Leptomycin B (LMB)	Sigma-Aldrich	Cat#L2913
Bufalin	Sigma-Aldrich	Cat#B0261
Phenylmethanesulfonylfluoride (PMSF)	Sigma-Aldrich	Cat#78830
DMSO	Sigma-Aldrich	Cat#D8418
Ethanol	Sigma-Aldrich	Cat#E7023
MG132	Millipore-Sigma	Cat#474790
Polybrene	Millipore-Sigma	Cat#TR-1003-G
Trametinib	Selleck Chemicals, MedChem Express, or Novartis	Cat#S2673 or Cat#HY-10999A

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Dabrafenib	Selleck Chemicals or MedChem Express	Cat#S2807 or Cat#HY-14660A
Fulvestrant	MedChem Express	Cat#HY-13636
Binimetinib	MedChem Express	Cat#HY-15202
Selumetinib	Selleck Chemicals or MedChem Express	Cat#S1008 or Cat#HY-50706
Recombinant ER α protein	ThermoFisher Scientific	Cat#A15674
Critical Commercial Assays		
TruSeq RNA Library Prep Kit	Illumina	Cat# RS-122-2001
KAPA Library Quantification Kit	Kapa Biosystems	Cat# KR0405
Deposited Data		
RNA-Seq	GEO	GSE142479
Experimental Models: Cell Lines		
MCF-7	ATCC	Cat#HTB-22; RRID:CVCL_0031
ZR-75B	A gift from Marc E. Lippman (Georgetown Univ., Med. Cntr.)	RRID:CVCL_5614
T47D	ATCC	Cat#HTB-133; RRID:CVCL_0553
Experimental Models: Organisms/Strains		
Athymic nude mice	Envigo	N/A
SCID/bg	Envigo	N/A
Oligonucleotides		
See Table S6 .	This study	N/A
Recombinant DNA		
pMD2.G	Addgene	Cat#12259
pSPAX2	Addgene	Cat#12260
pINDUCER11-scrambled shRNA	This study	N/A
pINDUCER11-NF1 shRNA clone 5	This study	N/A
pINDUCER11-NF1 shRNA clone 6	This study	N/A
pLentiCRISPR v2-scramble	This study	N/A
pLentiCRISPR v2-NF1 clone 1	GenScript	N/A
pLentiCRISPR v2-NF1 clone 2	GenScript	N/A
pDONR225-NF1	A gift from the RAS Initiative at the Frederick National Laboratory for Cancer Research at NCI	N/A
pCL-FLAG	Zheng et al., 2012	N/A
pCL-FLAG-NF1	This study	N/A
pCL-FLAG-NF1-R2258*	This study	N/A
pCL-FLAG-NF1-Y2285*	This study	N/A
pCL-FLAG-NF1-R2450*	This study	N/A
pCL-FLAG-NF1-R1362Q	This study	N/A
pCL-FLAG-NF1-K1444R	This study	N/A
pCL-FLAG-NF1-I417M	This study	N/A
pCL-FLAG-NF1-V1308A/I1309A	This study	N/A
pM-NF1	This study	N/A
pM-NF1-R1362Q	This study	N/A
pM-NF1-K1444R	This study	N/A
pM-NF1-I417M	This study	N/A
pM-NF1-I417A/I418A	This study	N/A

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
pM-NF1-V1308A/I1309A	This study	N/A
pDEST566-GST	This study	N/A
pDEST566-NF1-M2/GAP	A gift from the RAS Initiative at the Frederick National Laboratory for Cancer Research at NCI	N/A
SpCas9(BB)-2A-GFP(PX458)	Addgene	Cat# 48138; RRID: Addgene_48138
pGL4.70-RLuc	Promega	Cat#E688A
pGL2-ERE-Luc	A gift from Donald P. McDonnell (Duke Univ.)	Hall and McDonnell, 1999
5×Gal4-Luc	Promega	Cat#E2440
pVP16-ER α	A gift from Donald P. McDonnell	Chang et al., 1999
pVP16-SRC1	A gift from Donald P. McDonnell	Chang et al., 1999
pVP16-NCOR1	A gift from Donald P. McDonnell	Chang et al., 1999
Software and Algorithms		
ImageJ	Schneider et al., 2012	https://imagej.nih.gov/ij/
SoftWorx v7.0	GE Healthcare	N/A
FlowJo	FlowJo	N/A
Bowtie2	Langmead and Salzberg, 2012	http://bowtie-bio.sourceforge.net/bowtie2/index.shtml
RSEM v1.2.31	Li and Dewey, 2011	https://deweylab.github.io/RSEM/
R 3.3.4	R Core Team	N/A

LEAD CONTACT AND MATERIALS AVAILABILITY

Further information and requests for resources or reagents should be directed to and will be fulfilled by the lead contact Dr. Eric C. Chang at echang1@bcm.edu. All materials generated by this study are available upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS**Cell Lines**

The human cell lines, growth media, and general methods of cell culture have been previously reported ([Zheng et al., 2015](#)), unless otherwise indicated. All lines were routinely tested for mycoplasma contamination. Estrogen deprivation was achieved by seeding cells in phenol red-free media (DMEM for ZR-75B, MDA-MB-231, and RPMI1640 for MCF-7 and T47D cells) containing 10% charcoal-stripped fetal bovine serum (Sigma-Aldrich) for two days prior to the experiment. Note that MDA-MB-175VII is an NF1-null cell line, apparently carrying biallelic frameshift mutation *p.Y2285FS*5* ([Neve et al., 2006](#)).

The procedures for producing lentivirus, infecting breast cancer cells, and selecting for stable integrants were also conducted as previously described ([Zheng et al., 2015](#)). The cells stably expressing inducible shRNA were collected using FACS (Aria II, Becton Dickinson) two days after DOX treatment (2 μ g/ml) by examining the presence of turboRFP, which is expressed together with the shRNA from the same bicistronic transcript. Typically, >85% of transduced cells were RFP⁺. For *NF1* overexpression and CRISPR-mediated knock-out by two gRNA sequences, cells were transduced and selected in puromycin (1 μ g/ml) and pooled.

Animals

All animal work was approved by the Baylor College of Medicine Institutional Animal Care and Use Committee. For MCF-7 xenografts, prior to transplantation, 5-6 week old female nude mice (Envigo International) were ovariectomized and left to recover for two weeks before an estrogen “capsule” ([Robinson and Jordan, 1989](#)) (0.7 cm silicone tubing, Dow Corning) was inserted. These capsules contain 0.5 mg E2 mixed with silicone gel (Factor II) to keep the final weight of the filler at 2 mg. Three days later, one million human cancer cells were suspended in Growth Factor-Reduced Matrigel (BD Biosciences) and PBS and injected into the No. 9 mammary glands. When average tumor volume reached ≈ 200 mm³, the mice were randomized into different treatment groups, and the E2 capsule in the tumor-bearing mice was replaced with a fresh one, or with a tamoxifen pellet (5 mg/pellet, Innovative Research of America). DOX was added in the drinking water at 0.2 mg/ml to silence *NF1* expression. For PDX studies, WHIM16 tumors were engrafted into cleared mammary fat pads of SCID/bg female mice (Envigo International) and allowed to grow without exogenous E2 supplementation until tumors reached ≈ 200 mm³. Mice were then randomized into different treatment groups. Fulvestrant

was injected subcutaneously at 250 mg/kg weekly. Trametinib (1 mg/kg), dabrafenib (30 mg/kg), binimetinib (20 mg/kg), and selumetinib (20 mg/kg) were given daily as chow (Research Diets Inc.). Mouse body weight was measured twice weekly to monitor treatment toxicity.

METHOD DETAILS

Chemicals

Chemicals used are listed in [Key Resources Table](#). Note that with the exception of the animal experiments, in all other experiments involving E2, the water-soluble version was used. Ethanol was used to dissolve 4-OHT, while DMSO was used to dissolve trametinib, dabrafenib, fulvestrant, and selumetinib. We note that drug concentrations were selected such that fulvestrant plus the selumetinib combination can more easily produce an effect on the cells that is greater than either group alone.

Plasmids

Scrambled and *NF1*-targeting shRNAs (clone C5 and C6) in pGIPZ were obtained from Dharmacon. All nucleotide sequences used in this study are described in [Key Resources Table](#) and [Table S6](#). The shRNA clones were subcloned into pINDUCER11, with which cell lines stably expressing DOX-inducible scrambled or *NF1* shRNA were later created as described ([Zheng et al., 2015](#)). Unless otherwise mentioned, data obtained from cell lines expressing *NF1* shRNA C5 are shown in the figures, while the cells expressing C6 were also tested in most experiments. *NF1* CRISPR-Cas9 knock-out (KO) constructs (clone #1 and #2 in pLentiCRISPR v2) were purchased from GenScript, and scrambled gRNA sequences were synthesized and then cloned into pLentiCRISPR v2. pDONR225-*NF1* was a kind gift from the RAS Initiative at the Frederick National Laboratory for Cancer Research at NCI. The full-length *NF1* coding sequence in this vector has been extensively modified to facilitate expression studies without changing the amino acid sequence. To analyze its expression, an "*NF1* (NC)" primer set was used for RT-PCR. This *NF1* coding sequence is also refractory to both the C5 and C6 shRNA clones. *NF1* mutants were created by site-directed mutagenesis (QuickChange II XL Site-Directed Mutagenesis Kit, Agilent Technologies) using pDONR225-*NF1* as the template. These cDNAs were finally transferred into destination vectors pCL-FLAG and pM ([Chang et al., 1999](#)) to create pCL-FLAG-*NF1*, pM-*NF1*, pCL-FLAG-*NF1*-R2258*, pCL-FLAG-*NF1*-Y2285*, pCL-FLAG-*NF1*-R2450*, pCL-FLAG-*NF1*-R1362Q, pM-*NF1*-R1362Q, pCL-FLAG-*NF1*-K1444R, pM-*NF1*-K1444R, pCL-FLAG-*NF1*-I417M, pM-*NF1*-I417M, pM-*NF1*-I417A/I418A, pCL-FLAG-*NF1*-V1308A/I1309A, and pM-*NF1*-V1308A/I1309A. pDEST566-*NF1*-M2/GAP ([Bollag et al., 1993](#)), which expresses recombinant 6×His-MBP tag at the N-terminus of *NF1*-M2/GAP in *E. coli*, was also a gift from the NCI RAS Initiative. pDEST566-GST was built by transferring GST cDNA from pENTR-GST to pDEST566.

Generation of *NF1* Point Mutation Knock-in (KI) Cells Using CRISPR-Cas9

MCF-7 cells carrying homozygous mutations were generated by the Cell-Based Assay Screening Service core at Baylor College of Medicine (BCM). The general procedure is as described previously ([Ran et al., 2013](#)) and depicted in the right figure. Briefly, gRNA sequences were cloned into SpCas9(BB)-2A-GFP (PX458, a gift from Feng Zhang, Addgene plasmid #48138; <http://n2t.net/addgene:48138>; RRID: Addgene_48138). In addition to silent mutations that prevent Cas9 cleavage, each single-stranded oligodeoxynucleotide (ssODN) repair template also contains an engineered restriction site to facilitate identification of the KI allele. Cells were co-transfected with the CRISPR/gRNA plasmid and its corresponding ssODN template using the Neon transfection system (Thermo Fisher Scientific). The resulting GFP⁺ cells were plated by limiting dilution for single clone isolation. The genomic region surrounding each target site was PCR-amplified for validation by sequencing.

Assays for Cell Growth and Apoptosis

To compare cell growth between *NF1*⁺ and *NF1*^{KD} cells, cells stably expressing *NF1* shRNA were first seeded in estrogen-deprived medium, typically in triplicate, with DOX added at the same time. Two days later (Day-0), the medium was replaced with a fresh medium containing either vehicle control or compound(s) under investigation, with medium change every three days thereafter. The number of viable cells was measured using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay kit (Promega) six days later (Day-6). Cell growth between parental and *NF1* knock-out cells was similarly examined except no DOX was added. Apoptosis was measured by FITC-Annexin (Becton Dickinson) staining followed by FACS.

Generation of *NF1* Antibodies

A cDNA encoding amino acid residues 2471-2839 in *NF1* was subcloned into pRP259 ([Chang et al., 1994](#)) to express this C-terminal fragment of *NF1* (*NF1*C) as a GST-tagged protein in *E. coli* (BL21 DE3). Purified GST-*NF1*C was injected into rabbits (Thermo Fisher Scientific) or mice (Protein and Monoclonal Antibody Production Shared Resource at BCM) to generate polyclonal and monoclonal antibodies, respectively. The polyclonal antibody from one rabbit (*NF1* Ab-2, [Figure S5A](#)) was later affinity-purified against the same immunizing antigen. One hybridoma clone (mAb-376) was expanded *in vitro* and IgG was purified from culture medium by protein-G Sepharose column chromatography.

Immunoprecipitation (IP)

Cells grown in E2-deprived medium were treated with E2 (10⁻¹¹ M), 4-OHT (10⁻⁷ M), or the vehicle (ethanol) for 4 hrs before being isolated for whole cell or nuclear extracts. To conduct IP using whole cell extracts, cells were lysed in RIPA buffer supplemented with 1 mM

PMSF and protease and phosphatase inhibitors (Roche Applied Science). The cell lysates were pre-cleared with mouse IgG beads (Sigma, 3 hours at 4°C) before NF1 (mAb-376) or ER (F-10 monoclonal, Santa Cruz) antibody or the mouse IgG control (Santa Cruz) was added. Samples were incubated at 4°C overnight, followed by incubation with protein A/G agarose beads (Santa Cruz) for another 4 hours. All beads were finally washed three times with TBS (20 mM Tris-HCl (pH 7.5) and 150 mM NaCl). The bound proteins were eluted with 2× SDS sample buffer by boiling for 5 minutes and then examined by immunoblotting. To conduct IP using nuclear extracts, the same antibodies were pre-incubated with the protein-G Dynabeads™ (Thermo Fisher Scientific) overnight at 4°C before mixing with nuclear extracts which were prepared as described previously (Lanz et al., 2010). All beads were washed twice with NETN buffer (20 mM Tris-HCl (pH 7.5), 1 mM EDTA, 150 mM NaCl, and 0.5% NP-40), and once with PBS before elution and immunoblotting.

Immunoblotting

Cell lysates were generally prepared in RIPA buffer supplemented with protease and phosphatase inhibitors, and proteins were separated by SDS-PAGE before being transferred to nitrocellulose membranes. The primary antibodies used are listed in [Key Resources Table](#). The fluorescein-conjugated secondary antibodies were from Li-COR Biosciences, and the protein levels were quantified by an Odyssey infrared imaging system (Li-COR Biosciences).

RNA-seq

Estrogen-deprived MCF-7 cells were treated with E2 (10^{-11} M), 4-OHT (10^{-7} M), or ethanol (vehicle) before RNA was extracted after 24 hrs using RNeasy Mini Kit (Qiagen) according to manufacturer's directions. The E2 concentration used in this and the ChIP experiment was chosen because it can efficiently differentiate the growth between NF1⁺ and NF1-depleted cells (Figure 1E). Because the E2 concentration used was low, pilot qPCR experiments were conducted to determine that it takes 24 hrs after E2 stimulation to observe substantial difference in gene expression between these cells. MCF-7 CRISPR KI cells were simply grown in estrogen deprivation medium for 72 hrs before RNA extraction. The Genomic and RNA Profiling Core (GARP) at BCM constructed libraries with 250 ng of total RNA using the TruSeq RNA Library Prep Kit (Illumina). cDNA was generated from poly(A)-selected RNA. Libraries were quantified with the KAPA Library Quantification Kit (Kapa Biosystems) and were sequenced on the NextSeq 500 (Illumina) with paired-end 75bp reads and aligned to the hg19 (GRCh37) reference genome using RSEM v1.2.31 (Li and Dewey, 2011) and Bowtie 2 (Langmead and Salzberg, 2012).

Differential gene expression and fold change analysis was performed using EBseq (Leng et al., 2013) with FDR < 0.2 as a cutoff. Differentially expressed genes were subsequently used in Gene Set Enrichment Analysis (GSEA) for “Hallmark Pathways” in the Molecular Signatures Database (MSigDB) (Subramanian et al., 2005) and the top 10 enriched pathways were reported. For validation in clinical datasets, mRNA levels of the 1,107 genes identified from the MCF-7 cell line study were analyzed in TCGA and METABRIC ER⁺ breast cancer cohorts using cBioportal (Cerami et al., 2012; Gao et al., 2013). Genes in these cohorts that are differentially expressed between NF1-FS/NS and NF1-WT tumors were identified by t-test with p values cutoff at < 0.05. The differentially expressed genes in these clinical validation datasets were each similarly analyzed for “Hallmark” pathways enrichment as above (FDR<0.05). Clustering was performed using Hierarchical Clustering in R.

ChIP

The cells were seeded in E2-deprived medium. After 48 hrs, the cells were treated with E2 (10^{-11} M), 4-OHT (10^{-7} M), or the vehicle control (ethanol) for 45 min before ChIP, which was performed as described (Chen et al., 2008). Specifically, crosslinking was performed using 1% formaldehyde for 10 min at room temperature and quenched by glycine (final concentration of 125 mM). Cells were then scraped off the plate with ice-cold TBSE buffer (20 mM Tris-HCl, pH 7.5, 1.0 mM EDTA, 150 mM NaCl) and pelleted by centrifugation. Next, pelleted cells were resuspended in lysis buffer (10 mM Tris-HCl, pH 8.0, 0.25% Triton X-100, 10 mM EDTA, 100 mM NaCl) to release nuclei. The nuclei were further lysed in 1% SDS buffer (50 mM HEPES-KOH, pH 7.5, 1% Triton X-100, 0.1% sodium deoxycholate, 1% SDS, 2 mM EDTA, 150 mM NaCl) and sonicated using a Branson Sonicator to shear genomic DNA to an average fragment size of 200 to 500 bp. ChIP was performed with a commercially available antibody against ER- α (HC-20 and F10 for ChIP-qPCR, and F10 for ChIP-seq, Santa Cruz), a rabbit polyclonal NF1 antibody (A300-140A from Bethyl Laboratories; Ab-1), a polyclonal NF1 antibody made by us (above; Ab-2), a rabbit IgG control (Millipore) or a mouse IgG control (Santa Cruz) added to the same amount of chromatin after SDS was diluted to 0.1%. The precipitated DNA was isolated by phenol-chloroform extraction. To assess ERE occupancy by qPCR, fold-enrichment of amplified ERE levels in the ChIPed samples vs. those in inputs were calculated.

qPCR

RNA was isolated using the RNeasy kit (Qiagen), and cDNAs were synthesized from 5 μ g of total RNA using the SuperScript IV First-Strand Synthesis System (Thermo Fisher Scientific). Real-time PCR was performed with Fast SYBR Green Master Mix on a Light Cycle 96 (Roche Life Science) or CFX (Bio-Rad) Real-Time PCR system. The PCR primers used are described in [Table S6](#). The relative amounts of PCR products generated from each primer set were determined on the basis of threshold cycle (Ct) using GAPDH as the loading control.

ERE-Luciferase Reporter Assay

MCF-7 cells were seeded in E2-deprived medium for one day before being transfected with pGL2-ERE-Luc (Hall and McDonnell, 1999), which contains 3× vitellogenin EREs, for another day. The cells were then treated with 10^{-11} M E2 for 24 hrs. Cells were

also co-transfected with pGL4.70-RLuc (Promega, Madison, WI, USA) to express *Renilla* luciferase as an internal transfection efficiency control. The firefly and *Renilla* luciferase levels were measured using the Dual-Luciferase Reporter Assay kit (Promega).

The Mammalian Two-Hybrid Assay

The mammalian two-hybrid assays measuring the binding between ER and its coregulators have been described (Chang et al., 1999). Briefly, HEK293 cells were co-transfected by pM vectors expressing various versions of NF1 fused to the Gal4 DNA binding domain (DBD), as well as pVP16 vectors expressing various ER fragments fused to the VP16 transcriptional activation domain. These cells were also co-transfected to carry the firefly luciferase reporter 5×Gal4-Luc3 and the pGL4.70-RLuc, whose *Renilla* luciferase activity was measured to control transfection efficiency. Fusion protein expression levels were also assessed by Western blot. Luciferase activities were measured two days later. To determine whether the NF1-ER interaction can be modulated by E2 and 4-OHT, cells were estrogen-starved before transfection. E2 (10^{-11} M), 4-OHT (10^{-7} M), or the vehicle control was added one day post-transfection. The luciferase activity was measured after another day.

ER and NF1-M2/GAP In Vitro Binding Assay

E. coli BL21 (DE3) cells carrying either pDEST566-GST or pDEST566-NF1-M2/GAP were induced by 1 mM IPTG at 30°C for 4 hrs. The cell pellets were then resuspended in ice-cold MBP binding buffer (20 mM Tris-HCl (pH 7.4), 200 mM NaCl, 1 mM EDTA, 1 mM DTT, 1 mM PMSF, and protease inhibitors) and sonicated. The cell lysates were incubated with amylose magnetic beads (New England Biolabs) for 4 hrs at 4°C and washed by the MBP binding buffer. After elution (2× SDS sample buffer), the concentrations of bound proteins on the beads were quantified using BSA as the standard. Purified recombinant ER- α (10 ng, Thermo Fisher Scientific) was pre-incubated with 100 nM E2, 5 μ M 4-OHT, or ethanol for 1 hr at 4°C, and then mixed with 200 ng bead-bound NF1-M2/GAP or the GST control, which was pre-incubated with 1 mg/ml BSA in MBP binding buffer for 1 hr at 4°C to reduce non-specific binding. After 1 hr at 4°C, the bound proteins were eluted with 2× SDS sample buffer and examined by immunoblotting.

Cell Fractionation

The experiments were conducted as previously described (Suzuki et al., 2010). Leptomycin B (LMB) at 40 nM or ethanol (vehicle) was given to the cells grown in regular growth medium for 6 hours. To assess the influence of ER ligands, cells were first starved in E2-deprived medium and then treated with E2 (10^{-11} M), 4-OHT (10^{-7} M), or the vehicle control for 16 hours.

Immunofluorescence Deconvolution Microscopy

Cells were seeded and treated by LMB or ER-ligands (above) in 12-well plates with an 18-mm No. 1.5 coverslip. The fixation (4% formaldehyde), permeabilization (200 mM glycine/1X PBS, 0.1% Triton X-100), and blocking (5% goat serum) were performed as previously described (Cheng et al., 2011). The sample was incubated with NF1 antibody mAb-376 at room temperature for 2.5 hrs. We found that it is important to optimize the dilution factor for the secondary antibody to reduce background. Alexa-Fluor™ 488 conjugated goat anti-mouse IgG secondary Ab (Thermo Fisher Scientific) was added after a 1:1,000 dilution in the blocking solution and incubation was performed in the dark for 1 hr. The samples were then mounted to slides with a DAPI-containing mounting medium (Vector Laboratories). Imaging was performed at the Integrated Microscopy Core at BCM on a DVLive epifluorescence image restoration microscope (GE Healthcare). The system is equipped with an Olympus PlanApo 60×/1.42 N.A. objective and a pco.EDGE sCMOS_5.5 camera with a resolution up to 2,560 × 2,160 pixels. The filter sets used were: DAPI and FITC. Z stacks (0.2 μ m) covering the whole cell (~12 μ m) were acquired before applying a conservative restorative algorithm for quantitative image deconvolution using SoftWorx v7.0. Image J was used to quantify NF1 levels. For each cell a single focal plane dissecting the middle of the nucleus was chosen, from which two ROIs were created: ROI-1 encircles the whole cell while ROI-2 encircles just the nucleus. The reported relative NF1 nuclear levels were defined as: ROI-2/ROI-1.

ERE Pull-down Using HeLa Cell Nuclear Extract

These assays were conducted similarly to those previously described (Foulds et al., 2013). Briefly, 1 mg of HeLa S3 nuclear extract and 0.5 μ g of purified recombinant ER were added to 4 μ g of a 921 bp biotinylated 4× ERE DNA fragment immobilized onto 60 μ l Dynabeads™ M280 (Thermo Fisher Scientific). Different ligands were included in these recruitment assays. After washing twice in NETN and once in DPBS, the retained proteins were detected by immunoblotting.

QUANTIFICATION AND STATISTICAL ANALYSIS

All reported data were typically presented as mean \pm s.e.m. and pair-wise comparisons were analyzed by two-sided Student's t-test unless otherwise mentioned. The n values are either separate biological replicates or numbers of cells or mice, as indicated. Human tumor databases were analyzed using the R statistical packages. We note that throughout this paper *, p<0.05; **, p<0.01; ***, p<0.001; NS, Not Significant (p \geq 0.05).

NF1 Mutation Frequency in Patients

The extraction and general sequencing pipeline of cell-free DNA has been described previously (Lanman et al., 2015). Specifically, for NF1, most of its exons (except exons 1, 7, 15, 19, 22, 23, 29, 31, 51, and 56-61) were completely sequenced, and single nucleotide

variants as well as small indel events were analyzed. M1 and M2 are encoded by exons 11 (25 amino acids) and 29 (35 amino acids). cBio (Cerami et al., 2012) was used for somatic mutation and clinical data mining. Mutations were visualized using the GeneVisR (Skidmore et al., 2016) Bioconductor package. The cohort of primary breast cancers was from TCGA (TCGA, 2012), while the metastatic cohort was described (Lanman et al., 2015).

Patient Proliferation Status after Aromatase Inhibitor (AI) Treatments

Patients in the ACOSOG Z1031 trial (Ellis et al., 2011) were treated by AIs in a neoadjuvant setting, and their mRNAs before and after treatment were analyzed by Agilent microarray. A multigene proliferation score (MGPS) derived from mRNA expression of 772 genes was used to analyze proliferation status in the patient to assess treatment response (Ellis et al., 2017).

NF1 Expression Level Analysis in Patients

NF1 mutation types in TCGA (Ciriello et al., 2015) and METABRIC (Pereira et al., 2016) were mined from cBio (Cerami et al., 2012; Gao et al., 2013). NF1 mRNA levels in ER⁺ breast tumors from the METABRIC cohort (Curtis et al., 2012) together with survival information were obtained from OncoPrint (Rhodes et al., 2007). High and low NF1 mRNA levels were as defined above. Univariate Cox regression was analyzed using the Survival package for R.

Protein Levels Correlation Analysis

We have previously shown that protein co-expression is a strong predictor for co-functionality (Wang et al., 2017a). To identify proteins co-expressed with NF1, we used the LinkedOmics tool (<http://www.linkedomics.org>) (Vasaikar et al., 2018) to calculate the Pearson's correlation coefficient between NF1 and all other proteins in the CPTAC (Clinical Proteomic Tumor Analysis Consortium) breast cancer mass spectrometry dataset, which contains 105 breast tumor samples (Mertins et al., 2016). We ranked the proteins based on correlation coefficient scores and then analyzed them using Gene Set Enrichment Analysis (GSEA) in WebGestalt (Wang et al., 2017b) to identify enriched Gene Ontology (GO) molecular functions. As a control, we similarly analyzed p120GAP/RASA1.

DATA AND CODE AVAILABILITY

RNA-seq data are deposited in Gene Expression Omnibus (GEO) database, accession number GSE142479.